

# **A Comprehensive Review of Duchenne Muscular Dystrophy: Genetics, Clinical Presentation, Diagnosis, and Treatment**

---

## **ABSTRACT**

Duchenne Muscular Dystrophy (DMD) is a genetic disorder involving progressive muscle deterioration leading to loss of mobility, cardiomyopathy, and respiratory complications leading to an early death by the fourth decade of life. Males are affected more often as DMD results from a mutation in the dystrophin gene residing on the X chromosome. The DMD genetic mutation results in a complete functional lack of dystrophin, which culminates as an inadequate connection between the intracellular actin filaments and the extracellular skeleton of muscle. Boys affected by DMD clinically present with muscle weakness before age five, are often wheelchair-bound by age 12, and rarely survive beyond the third decade of life.

Traditional treatment strategies have focused primarily on quality-of-life improvement and have included the use of glucocorticoids and physical therapy. No cure currently exists, however many novel treatments for DMD are currently being explored. Some of these involve gene therapy, exon skipping, stop codon skipping, CRISPR technology interventions, and the use of a retinal dystrophin isoform. In this comprehensive review, we recapitulate the literature findings to summarize the history, epidemiology, genetics, clinical presentation, diagnosis, and current and future strategies for the treatment of Duchenne Muscular Dystrophy.

*Keywords: Duchenne Muscular Dystrophy; Dystrophin; Retinal Dystrophin; Antisense Oligonucleotide; Treatments; Diagnosis; Symptoms; Genetics*

## **1. INTRODUCTION**

Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disease caused by a mutation in the *DMD* gene encoding for the dystrophin protein. DMD is characterized pathologically as a complete absence of the cytoskeletal protein [1]. DMD is characterized clinically by progressive muscle weakness with the distribution of predominant muscle fragility in the proximal extremities, neck, and chest [2]. DMD is the most common of the muscular dystrophies, and one of the most common fatal neuromuscular disorders, affecting 1 in 3,500 newborn boys [3]. The clinical presentation begins early in childhood with progressive muscle wasting and weakness, eventually leading to death. The protein defect is present at birth but is not typically clinically observed and diagnosed until the second or third year of life. This disease eventually leads to the inability to walk with an associated wheelchair requirement around age 12, severe scoliosis secondary to muscle weakness, and eventual death due to cardiac and/or respiratory failure by the mid-twenties, especially

in those patients not choosing ventilator support [2]. The human *DMD* gene resides at locus Xp21.2 and produces a rod-shaped cytoplasmic structural protein primarily in skeletal muscle with isoforms in cardiac muscle, smooth muscle, brain nerve cells, and the retina [4–6]. The *DMD* gene is 2.3 Mb in humans with 79 exons, producing a 14 kb RNA and 427 kDa protein [5,7,8].

One-third of DMD cases are due to a *de novo* mutation, and two-thirds of cases are of familial origin, usually from a female carrier [9]. Becker Muscular Dystrophy (BMD) is a less severe form of muscular dystrophy in which similar symptoms appear but with a slower and less severe progression [10]. Statistical analysis found the global prevalence of DMD to be three times higher than the rate of BMD [11]. Global DMD prevalence is around 7.1 per 100,000 males and 2.8 per 100,000 of the general population. DMD incidence was found to be 19.8 per 100,000 live male births [12,13]. It was found that from 2006 to 2015 in the U.S., 3,256 deaths were due to DMD in the male population under 40 years of age, with 71% of these mortalities being confined within the age range of 15 to 29 years of age [14].


Though it is unusual for X-linked disorders to demonstrate different frequencies across different racial groups, muscular dystrophies (MD) have drastically different affected racial populations. It appears MD are statistically higher in the Caucasian male population than males in other racial groups. Caucasian American males experience an average annual death rate of 0.43 per 100,000 from MD, compared to that of African American males, which have a rate of 0.28 per 100,000 [14]. Native Americans and Alaska Natives are found to have 0.20 deaths per 100,000 and Asian and Pacific Islanders with 0.21 deaths per 100,000. Hispanic white and non-Hispanic whites also had different rates of MD incidences. Hispanic whites have a death rate from MD of 0.31 per 100,000, as compared to non-Hispanic whites with a rate of death of 0.46 per 100,000 [14].

Children born with DMD are of normal height and weight at birth but often fall below the expected growth curves during early childhood. Boys born to families without a past medical history of DMD are normally diagnosed during the fourth year of life. Dystrophic myopathy presents with rapid, progressive muscle degeneration and a loss of functional skeletal muscle over time. Motor delays or abnormal gait are the most common presenting symptoms [15]. Other presentations may include communication disorders such as language delays, or overall global developmental delays [15].

## 2. MOLECULAR PATHOLOGY OF DMD DISEASE

The *DMD* gene is located at Xp21 which produces the sarcolemma protein dystrophin [16]. The immense dystrophin gene is constructed of 79 exons and spans more than 2,200 kb, making up 0.1% of the entire human genome [17]. Full-length dystrophin is a 427 kDa structural protein in muscle tissue, responsible for the integrity of muscle cells. This muscle isoform links integral membrane proteins to the actin cytoskeleton and is thought to stabilize the sarcolemma during muscle activity [18]. The dystrophin protein contains four functional domains: an N-terminus actin-binding domain (ABD1), a long spectrin-like repeat domain, a cysteine-rich domain, and a C-terminus domain [5,18]. The ABD1 domain binds to F-actin filament and cytokeratin 19 (K-19) in muscle [19–21]. The long spectrin-like repeat is the flexible cytoskeletal central rod portion of the dystrophin protein, which also contains a second actin-binding site, namely an actin-binding motif (ABD2) providing further actin-binding ability [19,22]. The cysteine-rich domain interacts with syntrophin proteins and the C-terminus interacts with the dystrophin-associated glycoprotein complex which includes sarcoglycans and dystroglycans, dystrobrevin, and syntrophin [23–27] (Figure 1). In addition, dystrophin binds to neuronal nitric oxide synthetase (nNOS) in the sarcolemma [28]. nNOS

produces nitric oxide which mediates vasodilation of muscle blood supply, playing a role in muscle fatigue [29].



**Figure 1. Dystrophin-Glycoprotein Complex.** Dystrophin interacts with numerous proteins of the cell including actin, dystrobrevin-alpha, syntrophins. The glycoprotein complex also includes sarcoglycans and dystroglycans, and nitric oxide synthetase (nNOS). This complex provides membrane stabilization in muscle cells.

The *DMD* gene includes at least **eight independent promoters**. Three of these promoters express full-length dystrophin proteins while the remaining two promoters occur near the coding sequence for the C-terminus, containing the last domain [18]. Several surrogate forms arise from alternative splicing of six exons of the C-terminus. This great structural diversity of dystrophin suggests this protein may serve several distinct anatomical, genetic, and biochemical functions. The *DMD* gene produces several diverse isoforms driven by different promoters including Dp427 (dystrophin protein 427 KDA) in muscle, lymphoblasts, brain, Purkinje cells of the cerebellum, Dp260 in the retina, Dp140 in the brain and kidney, Dp116 in Schwann cells, Dp71 in brain and retina, and Dp40 in the brain [30–35].

In muscle cells, the dystrophin complex localizes at the cell membrane and connects the intracellular cytoskeleton to the extracellular matrix. It has been hypothesized that dystrophin acts as a membrane stabilizer during muscle contraction to help prevent contraction-induced damage [17]. Dystrophin functions to provide stability and structure between the actin filaments and the sarcolemma of **muscle** [36–38]. This primary function provides mechanical reinforcement to the sarcolemma and helps protect the cell membrane from the stress established during cycles of muscle contraction and relaxation [37]. These interactions between various proteins could induce conformational changes in calcium channels, resulting in increased calcium channel activity. Enhanced calcium influx can cause oxidative stress in muscle cells, which can progress to mitochondrial dysfunction and result in cell apoptosis [39]. Due to this increased calcium influx in DMD, measurements of heightened intracellular calcium are an important initial clinical finding in DMD [2]. Therefore, it can be concluded that interactions between sarcolemma-associated proteins, like dystrophin, and calcium channels are relevant to the pathophysiology of muscular dystrophy. In DMD, the functional loss of dystrophin results in the destabilization of the entire dystrophin-

glycoprotein complex. There has been additional new evidence that an error in the assembly of the nuclear lamina could be a shared feature of muscular dystrophy and that in addition to dystrophin's structural role, the dystrophin complex could play a role in cellular signaling for activities such as mechanical force transduction and cell adhesion [17]. In the absence of dystrophin, severe muscle dysfunction, and wasting occur, as seen in DMD [40]. With only reduced dystrophin, as in BMD, similar symptoms appear with a slower and less severe progression [41].

### **3. DMD GENETIC MUTATIONS**

The loss of dystrophin protein in DMD occurs via various genetic mechanisms affecting dystrophin expression. Several exons have been described as deletion hotspots for muscular dystrophy diseases, including exons 3-19 and 42-60 [42]. The possible genetic mutations that can cause DMD is vast. These include deletions, duplications, insertions, and nucleotide changes. However, 50-70% of DMD mutations are large deletions, of which most are deletions that span one or multiple exons [42,43]. Next most prevalent (~20%) genetic changes are small deletions, insertions, and nucleotide point mutation changes that result in stop codons. The next category of genetic mutations in DMD is large duplications, making up ~12% of diagnosed cases. Any left-over genetic mutations fall into the division of subexonic insertions, deletions, splice mutations, and missense mutations [43]. There appears to be no correlation between the size of the gene deletions in DMD and the severity of the disease [44].

Large N terminus deletions typically lead to variable but serious muscular dystrophy phenotypes. Proximal rod domain deletions result in mild or atypical muscular dystrophy phenotypes, possibly proving this domain relatively expendable. Distal rod deletions are usually present with BMD phenotypes. However, DMD usually results from deletions of the C terminus domain [45]. DMD patients' western blots display quantitative evidence of little or no dystrophin protein present in their cells. This complete lack of dystrophin contrasts with patients that have moderately reduced dystrophin levels and result in phenotypes with milder forms of muscular dystrophin diseases such as BMD or mild atypical myopathy [18]. The difference in phenotype between DMD and BMD appears to be due to reading frame disruption [46,47]. An out-of-frame deletion of *DMD* typically produces an unstable mRNA and shortened dystrophin, which is eventually destroyed. This destruction leads to the DMD phenotype and complete lack of dystrophin [46]. The BMD phenotype is the result of in-frame deletions, maintaining a functional but less-effective dystrophin which is smaller in size than normal dystrophin and is usually expressed in lower amounts [46]. The mutated protein transcribed from these frameshift mutations is vulnerable to the protective mechanism of nonsense-mediated mRNA decay. This surveillance pathway serves to reduce gene expression errors caused by a premature stop codon. The products of the transcription that surpass this mechanism are unstable due to the carboxy-terminal truncated protein and are commonly degraded, leaving little or no dystrophin protein produced in the cell [42].

These phenotypes suggest that not only is the location of deletion important for determining the severity of muscular dystrophy diseases, but the overall levels of dystrophin expression and function also play a crucial role. This explains not only the broad range of dystrophin isoforms but also the extremely diverse clinical phenotypes associated with muscular dystrophin diseases.

Almost two-thirds of DMD mutations are genetic deletions that span one or multiple exons [42]. As previously discussed, these deletions tend to group around two mutational hotspots. The most common deletion is exon 45 to exon 55, representing up to 74% of deletions, which removes a central portion of the rod domain [47]. The second most common deletion

hotspot accounts for around 15% of deletions and is located at exon 3 to exon 19, which removes all or part of the actin-binding domain and a portion of the rod domain [42]. Possible deletions in DMD patients are quite heterogeneous, with the top 21 most common deletions accounting for only 45% of deletions expressed in DMD patients [48].

The distribution of deletion breakpoints is greatly disseminated in the proximal region deletion hotspot and the distal deletion hotspot, which only contain a few introns. This proximal deletion hotspot distribution accounts for the high diversity in possible deletion events in the dystrophin protein. There have been 30 observed breakpoint sites, but the most frequent deletion breakpoints occur at intron 44 and account for 20% of these deletion breakpoints [47]. Intron 47 is the second most common site, making up ten percent of these starting breakpoints. Intron 50 is the third most common breakpoint site and comprises only eight percent of the deletion breakpoints [48].

Small deletions are the second most frequent type of mutation, accounting for around 22% of all mutations. Of the total number of small deletions, 40% result in a nonsense mutation, 32% result in frameshift mutations, 27% result in splice site mutations, and 1% to 2% result in missense mutations [47]. The clinical severity of these small deletions depends on the occurrence of reading frame disruptions and the point of premature termination of dystrophin protein synthesis.

Nonsense mutations make up 40% of small deletions, which translates to around 9% of all mutations. Transitions are the most common mutational event in nonsense mutations and lead to premature stop codons, with transversions being the second most common. The second most common independent small deletion is a frameshift mutation. However, frameshift mutations can result from small deletions, insertions, or duplications of several nucleotides. Splice mutations are the third most common small deletion. However, splice mutations rarely affect sites other than the two highly conserved "AG" and "GT" dinucleotides in DMD patients [47].


Gene duplications in DMD patients express even greater diversity than that of DMD deletions. Nearly 120 distinct large duplications have been identified and reported in DMD patients, with 70% of those having only been detected once [47]. The most common duplication is located at exon 2. This duplication is noted exclusively in DMD patients and while being the most common, accounts for only 9.8% of discovered duplications in DMD. Of the identified duplications, 98% of starting duplication breakpoints occur at intron 1 [47]. However, in contrast to deletions, there were no discrepancies in duplication sizes identified according to their location within the gene.

The reading frame rule holds true for 96% of DMD patient mutations. The 4% exception to this rule consists mainly of in-frame deletions starting at exon 3 in the actin-binding domain or in-frame duplications in the cysteine-rich domain [46]. This rule also explains the differences in skeletal versus cardiac muscle phenotypes due to differences in mRNA processing or loss of domains that have specific functions in each of these tissues. **Deletions** of both the cysteine-rich domain and the C terminus domain result in the DMD phenotype. In addition, both the cysteine-rich domain and C terminus domain have been highly conserved in evolution, suggesting the importance of these domains for proper dystrophin function [47]. The pathofunctional map formulated from DMD deletion analysis emphasizes the importance of the cysteine-rich and C terminus domain and illustrates that mutations of these domains are far more detrimental to the function of the dystrophin protein than are the N terminus and rod domain mutations.

Female carriers of a mutated *DMD* gene may show some symptoms related to carrier status, a status that can arise from a variety of genetic mechanisms including normal karyotype with skewed X chromosome-inactivation resulting in lower dystrophin levels, 45X, or Turner mosaic karyotypes, balanced X-autosome translocations with breakpoints in Xp21 within *DMD*, and uniparental disomy of the X chromosome [49–51]. Manifesting female carriers can exhibit minor muscle weakness and cardiac issues due to the process noted [52].

#### 4. CLINICAL DISEASE PRESENTATION

DMD primarily affects young males due to the *DMD*'s gene location on the X chromosome [53]. The clinical presentation of DMD has features of muscle weakness, muscle wasting, and fatigue [54]. These symptoms are usually first clinically evident between ages two to six years old and progressively get worse over a patient's lifetime [55]. Five signs/symptoms classically identify the first symptoms of DMD. Gross motor delay is the most common presenting sign/symptom, found first in 42% of children with muscular dystrophies [15]. The presence of gait abnormalities such as toe-walking is also a common initial symptom, followed by delays in beginning to walk, learning problems, and speech delays. The characteristic proximal weakness of DMD affects the lower extremities earlier and more aggressively than the upper extremities, eventually requiring the use of a wheelchair (typically by age 12). Evaluation of neck flexors will usually reveal weakness, such as not being able to lift the head when supine. This finding is useful when distinguishing DMD from other milder forms of muscular dystrophies [56]. Because of progressive muscle weakness, changes in stature and movement continue throughout childhood. A waddling gait, difficulty walking and running, difficulty climbing stairs, and frequent falls are common. The clinical sign of Gowers maneuver can also be observed in patients with DMD, characterized by fulfilling the standing position from a seated or supine position on the floor by first moving to a position of all fours, raising the posterior, and “walking” their hands backward and then up their body to raise the upper half of their torso [57] (Figure 2).



**Figure 2. Gower's Sign.** Gower's sign is a classic physical exam finding in DMD usually seen in children four to six years old. Weakness in lower extremity musculature forces patients to utilize their upper extremities to help arise from a prone position (1). The patient uses their shoulders to initiate standing up (2) then uses their hands to support themselves

on their legs (3). Finally, the patient moves their hands cephalad along their body to stand up (4, 5).

Spinal curvature disorders secondary to muscle weakness and inability to support the weight of the upper body are also prevalent. Scoliosis is the most common, but lordosis and kyphosis are also seen. Uniquely, DMD patients typically also present with enlarged calves, buttocks, shoulders, and tongue early in the disease course [58,59]. These enlargements begin as true tissue hypertrophy but later become pseudohypertrophy as muscle is replaced with connective and adipose tissue [15]. The movement of muscles controlled by cranial nerves is spared, with the exception of the sternocleidomastoid muscle of cranial nerve 11 [56]. Sleep disorders also occur in DMD patients. Obstructive sleep apnea is the prevailing sleep disorder during the first decade of life in one-third of patients with DMD [60]. During the second decade of life, boys with DMD develop hypoventilation during sleep, causing respiratory acidosis.

In addition to physical complications, patients with DMD are also noted to have intellectual disabilities. These include both learning difficulties and behavioral issues [61,62]. The dystrophin protein is not only present in skeletal and cardiac striated muscle but can also be observed as isoforms in the central nervous system and retina [63]. Thirty percent of children diagnosed with DMD suffer from an intellectual impairment, having an intellectual quotient (IQ) less than or equal to 85, which is one standard deviation below the accepted population average of 100 [64]. Verbal IQ is noted to be more impaired than performance IQ, explaining the common speech delay seen in these patients. There has been no correlation found between increased intellectual disability and the severity of generalized weakness. In addition, some patients appear to have a comorbid autism spectrum disorder, attention deficit hyperactivity disorder, or obsessive-compulsive disorder [65,66]. It is important to note, however, that unlike the muscular component of the disease, the intellectual component is not progressive [67]. These patients may require specialist teachers and/or neuropsychologists and access to these specialists should be made available for DMD patients at a young age to help assess the patients' possible needs and provide guidance.

Orthopedic complications are also commonplace in patients suffering from DMD. As stated earlier, scoliosis develops in most children with DMD. The presence of scoliosis is a key factor in the decreased pulmonary vital capacity found in DMD patients [68]. The increased incidence of falling due to muscular dystrophy and the associated muscle weakness leads to more long bone fractures in this population than in the general population [69]. Fractures are also partly due to the development of osteoporosis in most children with DMD. Osteoporosis can occur due to the continuous treatment with glucocorticoids and/or lack of weight-bearing exercise due to muscle loss. This continual loss of bone minerals such as calcium and phosphate lead to decreased bone density, resulting in frequent fractures. Osteoporosis progression begins even during the ambulatory portion of this disease process and continues throughout life.

Cardiomyopathy is an expected development in the DMD disease evolution. Patients will show cardiac symptoms including increased creatine kinase and transaminase levels along with irregular heartbeat [70–74]. Cardiac fibrosis leads to a variety of cardiac diseases including, and most commonly, dilated cardiomyopathy, resulting in the disruption of heart rate, rhythm, and conduction [74]. Cardiomyopathy usually appears in DMD patients between the ages of 10-15 years of age and is the second most direct cause of death, yet some sources suggest it is becoming the leading cause of death as quality-of-life care and ventilator support has led to longer lifespans with more opportunity to develop cardiomyopathy [75]. Cardiac pathology can present as early as ten years of age and is present in all patients over 18 years old. Though cardiac involvement is prevalent among the

DMD population, about three-fourths of patients under the age of 18 are asymptomatic due to the skeletal muscle disease involvement causing physical inactivity outpacing the cardiac muscle pathology [74].

Respiratory complications are eventually present in all patients with DMD and commonly are associated with the cause of death. Respiratory complications result from weakness in the diaphragm and accessory breathing muscles [76]. Restrictive lung disease is inevitable in all DMD patients and leads to chronic respiratory insufficiency [77]. Vital capacity (VC) is regularly evaluated in DMD patients to monitor respiratory health throughout their life. In boys with DMD, VC usually increases until around age ten years and then decreases at a rate of 8-12% per year [77]. Dysphagia is also present later in DMD [78].

## 5. DIAGNOSIS

The diagnosis of DMD is usually first suspected when a child exhibits muscle weakness, Gowers' sign (a clinical observation in which DMD patients 'walk up' their legs to attain a standing position) (Figure 2), scoliosis, difficulty walking, or other symptoms listed in the previous section [57]. The diagnosis of DMD can be confirmed by many laboratory tests including blood tests for elevated creatine kinase levels, multiplex PCR, and high throughput DNA sequencing [71,79,80].

As innovative technologies emerge, genetic counseling and prenatal diagnosis are becoming utilized more often. Prior to delivery, almost all fetal muscular dystrophies can now be discovered using these technologies. Prenatal screening includes techniques such as amniocentesis and chorionic villus sampling [81,82] and relative haplotype dosage (RHDO) analysis of maternal plasma to sequence the fetus genome from cell-free fetal DNA fragments in maternal plasma [83]. Preimplantation genetics can also be used by removing the blastomere following in-vitro fertilization, followed by DNA extraction and analysis [84].

One of the initial diagnostic tools used when DMD is suspected is a serum creatine kinase (CK) test [2]. Blood CK levels can be elevated ten times the normal values in newborns with a dystrophin disease [85]. Blood sample measurements of serum CK is a straightforward and inexpensive test that can be performed in most hospitals. DMD serum CK levels are elevated from birth and detection at this time will help provide early diagnostic intervention and improve patient quality of life over the course of the disease.

Another common method to diagnose DMD is a muscle biopsy to observe skeletal muscle histology. Muscle biopsy and dystrophin analysis can be useful to confirm a DMD diagnosis when genetic testing is negative or a genetic variant of unknown significance is revealed [86]. All dystrophies share histological findings of abnormal variations in muscle fiber size and necrosis, presence of tissue macrophages, and degree of replacement of muscle mass by connective and adipose tissue depending on the stage of the disease [2]. An open muscle biopsy must be performed to ensure adequate amounts of muscle tissue are available to determine the type of muscular dystrophy. However, a needle biopsy may be appropriate if the differential diagnosis includes only DMD [87]. Once the muscle sample is obtained, the main analysis for DMD includes immunocytochemistry and immunoblotting for the dystrophin protein [88]. It is crucial to differentiate between the total or partial absence of the dystrophin protein to conclusively distinguish between DMD and other dystrophinopathy phenotypes. Patients with DMD will have no dystrophin on a western blot (or nearly none), while BMD patients will have reduced dystrophin that is smaller (80%), normal size (15%), or larger (five percent) [89]. In DMD patients, the finding of less than five percent of normal dystrophin is diagnostic [1,90]. In BMD patients, a finding of 20-100% of normal dystrophin

levels are diagnostic [1,90]. Genetic testing is required after a positive muscle biopsy diagnosis of DMD.

Some providers and patients may find it appropriate to omit the muscle biopsy test in favor of continued clinical investigation with genetic testing due to the invasive and painful nature of the biopsy. If genetic testing is performed and no mutation is identified in a patient with elevated serum CK levels and DMD symptoms, the next diagnostic evaluation would be a muscle biopsy. Newer clinical techniques have also been explored for the diagnosis of DMD. The use of MRI (magnetic resonance imaging) and ultrasound to evaluate muscle size and progressive changes have been proposed as novel non-invasive techniques for DMD diagnosis [91,92].

Genetic diagnostic testing is designed to perform a conclusive quantitative analysis of dystrophin genes to identify most mutations resulting in the DMD phenotype, including common deletions and duplications. Testing for large deletions or duplications should be done first since they are more common (70-80% of cases) than point mutations (20-30% of cases) [93]. If the minimal genetic diagnostic testing reveals nothing, it will be followed by a full gene sequencing qualitative approach [94]. Common genetic diagnostic tests include identifying dystrophin mutations via multiplex PCR, multiplex ligation-dependent probe amplification, comparative genomic hybridization, and next-generation sequencing.

Multiplex PCR amplifies fragments of the dystrophin gene and analyzes them simultaneously. The benefits of using the multiplex PCR diagnostic tool are its wide availability and lack of expense. However, this method only detects deletions, so can only be used as a first step diagnostic tool [88]. If the result is negative, another quantitative diagnostic technique will have to be performed. Multiplex PCR also does not cover the whole dystrophin gene, but rather can only identify up to ten different exons in a single reaction. The targeted exons are usually located at hotspots but regardless, characterization of the mutation may not be a complete picture. However, endpoints of many deletions can be determined, which provides insight into the possible phenotype and severity of the disease due to endpoint effects on the translational reading frame [95].

Multiplex ligation-dependent probe amplification (MLPA) is currently one of the most widely used quantitative methods for identifying DMD [96]. MLPA can effectively genetically screen both symptomatic DMD patients as well as carrier females with MLPA or array-MLPA [97]. MLPA simultaneously tests all 79 *DMD* exons of the dystrophin gene and analyzes the gene for the structural modification and the presence of copy number variations through a multiplex polymerase chain reaction event. These identified copy number variations signify the presence of deletions or duplications that indicate disease.

Comparative genomic hybridization (CGH) scans the full dystrophin gene while searching for copy number variations using the oligonucleotide-based array [96]. Many array probes are used to help eliminate the possibility of false positives due to single nucleotide polymorphism. CGH can be used specifically if the diagnostic physician believes that the mutation is in an unusual location. CGH allows for the use of custom arrays that target the area of interest on the dystrophin gene but still maintain the appropriate resolution for conclusive results. The full view of the dystrophin gene allowed by the CGH diagnostic technique allows for the investigation of regions not routinely characterized such as the intron and 3' and 5' regions. This allows for CGH to detect unusually complex mutation arrangements and accurately define the mutation breakpoints [98]. CGH is highly valued for its dual ability to detect DMD molecular diagnosis and specific DMD gene mutations. The CGH technique is not only useful for clinical diagnosis but can also be readily used in DMD research to investigate non-coding regions for the etiopathogenesis of mutations for

diagnostic implications [98]. CGH can also complete the complex task of defining breakpoints of large rearrangements to assist in the understanding and correlation of genotype versus phenotype in DMD.

Next-generation sequencing (NGS) includes a vast variety of technologies, each of which has its own unique biochemical strategy. A full evaluation of the *DMD* gene requires not only a molecular quantitative analysis to detect copy number variations, but also genomic sequencing, both of which NGS can help provide. NGS also allows the remaining rare mutations that are not identified by the two previously stated methods to be diagnosed by more specific transcript analysis. One study showed NGS could accurately diagnose up to 92% of DMD/BMD patients [80]. Moreover, next-generation high throughput DNA sequencing techniques can be combined with MLPA to increase the accuracy of results [99,100].

Fluorescence *in situ* hybridization (FISH) can be used for large deletions and duplications but is not common [101]. Other genetic techniques used in diagnosing *DMD* deletions and duplications include qPCR, and chromosomal microarray analyses (CMA) [102,103]. If a large mutation is not detected, DMD can be genetically diagnosed via scanning for point mutations. Small point mutation detection is often done via denaturing high-performance liquid chromatography and direct sequencing [104,105].

If an analysis by one of these listed techniques uncovers and identifies the full characterization of the dystrophin mutation, then no further testing through other diagnostic techniques is advised. However, if the deletion or duplication test is negative, further sequencing should be completed on the dystrophin gene to pinpoint any small deletions or point mutations [94]. A full and complete characterization of the dystrophin mutation should be performed, locating all deletion endpoints and point mutations. This allows all the information gathered to be implemented in concluding how the patient's specific mutation will affect the dystrophin protein gene's reading frame. This reading frame correlation is the main key to determining the patient's phenotype from all the possible variations in dystrophinopathies. Furthermore, this genetic understanding may allow the patient to participate in mutation-specific gene therapies currently on trial [88].

## **6. TRADITIONAL TREATMENT STRATEGIES AND PROGNOSIS**

Unfortunately, there are no current medical treatments that will significantly change the course of DMD. The only treatments currently available aim to temporarily maintain the patient's general overall health, manage symptoms, and improve the patient's quality of life. Corticosteroids, specifically glucocorticoids, have traditionally been used to slow the decline in muscle strength of DMD patients. It is believed glucocorticoid therapy helps DMD patients by reducing muscle inflammation [106]. Improvements can be measured in decreased Gowers' time, distance walking time, stair climbing time, increased weight workouts, leg function grade, and forced vital capacity volume [107]. Regrettably, the effectiveness of corticosteroids only lasts from 6-24 months and does not alter the overall mortality of DMD [107].

There are two main steroid treatments regularly recommended for DMD patients, prednisolone and deflazacort. It is suggested these steroid treatments begin at the point of complete motor development before any muscle deterioration begins [88]. Prednisolone and deflazacort are thought to be equally proficient at preserving muscle integrity, however, they each exhibit their own distinct side effects, with varying degrees of severity. Recent research has suggested deflazacort might be superior to prednisolone for DMD progression delay,

along with fewer side effects. However, deflazacort is currently more cost prohibitive than prednisolone [108].

Respiratory failure is a common cause of death in patients with DMD, and respiratory status should be monitored closely throughout the patient's life. Pulmonary function tests should be conducted regularly, starting at DMD diagnosis. Each respiratory function evaluation should include oxyhemoglobin saturation and spirometry testing. Spirometry should include forced vital capacity (FVC), first-second forced expiratory volume (FEV1), maximal mid-expiratory flow rate, maximum inspiratory and expiratory pressures, and peak cough flow [109]. To avoid and monitor hypercapnia, awake carbon dioxide tension should be evaluated yearly through capnography. Patients should also be evaluated for other non-pulmonary respiratory disorders such as obstructive sleep apnea, oropharyngeal aspiration, gastroesophageal reflux, dysphagia, and asthma [109]. Patients confined to a wheelchair should also receive annual laboratory studies of complete blood counts, serum bicarbonate concentration, and chest radiography [109].

Once respiratory insufficiency is found, it can be treated with intermittent noninvasive positive-pressure ventilation (NIPPV) therapy [110]. Many patients choose elective tracheostomy when more invasive ventilatory support becomes necessary, to help ensure sufficient lung function to assist in reaching the third decade of life [2]. Antibiotics should also be prescribed at any sight of infections of the respiratory tract, to cease any further lung function deterioration. DMD patients should also expect to eventually receive ventilatory support to aid in treating hypercapnia symptoms, improve quality of life, lengthen life span, and diminish the need for emergency hospital visits [109].

Cardiac ailments are also common in DMD disease processes. Complete cardiac evaluations should be performed on children as soon as a DMD diagnosis is made and should continue throughout their lifetimes, at the minimum biannually. Commonly performed tests are electrocardiography and echocardiography. It is common for DMD patients to be late in the disease process when cardiac signs and symptoms are first noted, due to cardiac symptoms being masked for a prolonged period by physical inactivity. Symptoms of cardiac distress should be treated with a diuretic, angiotensin-converting enzyme (ACE) inhibitor, digitalis glycosides, or beta-blocker depending on the individual situation [111]. Immediate detection of cardiomyopathy in DMD is crucial for the best patient outcomes.

Any form of surgery is not recommended in the early course of the DMD disease process [112–114]. Possible detrimental outcomes from surgeries could arise from an anesthetic risk or extended periods of bed rest. Eventually, disease contractures might require treatment with surgical correction procedures to help maintain extremity ambulation. Scoliosis surgical correction, specifically through the Luque technique, is also becoming more accepted in DMD patients to improve sitting comfort and maintain full vital capacity lung volume [2]. Other surgeries may also help maintain lung function, adding additional years onto the life expectancy of DMD patients.

DMD patients may benefit from a variety of non-allopathic treatments, including physical therapy, occupational therapy, speech-language therapy, and nutritional monitoring [54]. The goals and development of such therapies should include a thorough assessment of the patient's disease progression and specific objectives attempting to be reached. The addition of a regular physical therapy regime is important in maintaining physical functioning. Physical therapy should begin in early childhood and continue throughout life. The overarching goal of physical therapy is to help DMD patients preserve muscle strength and mobility [115,116]. Many of the physical therapy exercises utilized include passive stretching of major joints multiple times per week [54]. Physical therapy is also thought to help prevent

muscle contractures common in DMD patients [67]. DMD patients should also engage in regular low-intensity exercise to avoid muscle atrophy. In addition to physical therapy, occupational therapy aims to maximize functionality and independent capacity for patients. Occupational therapy can help reach these goals by assisting DMD patients in finding the most appropriate wheelchairs and equipment throughout the progression of the disease and help ensure a safe home environment. Many DMD patients may also eventually suffer from dysphagia, which may benefit from a referral to a speech-language pathologist. Here patients can receive a swallowing assessment and additional therapy to limit complications. Finally, patients' nutritional status must be monitored, with particular attention to intake of Vitamin D and calcium to maintain bone health [54].

Although the physical characteristics of dystrophy diseases are most frequently the focus, it is important not to forget the mental hardships brought on by this disease. Four quality-of-life domains of DMD patients have been recognized and studied. These include physical health, social relationships, physiological status, and well-being [117]. The physical domain includes pain in its analysis. It has been found that patients with DMD have impaired quality of life in the physical domain that is relative and reactive to the tangible progression of DMD disease status, including the decline in ambulation over time. Though it may seem apparent, arm function has also been associated with several of the quality-of-life domains, so it is essential to keep upper limb function for as long as medically possible [117]. In addition, the social and physiological domains are also found to be more impaired than healthy children of the same age. Unfortunately, the well-being domain quality of life is also found to be lower than the general population and usually underestimated by caregivers and guardians [117]. It is suggested that along with medical interventions, patients should also be encouraged to participate in social activities to improve their quality of life. There should also be predetermined preparation for transitioning DMD patients from pediatric medical care and educational programs into adult care to limit stress from this change.


Over the years, advancements in science and technology have had significant effects on patients with DMD. Historically DMD patients died in their adolescent years or early twenties, however, DMD patients are now living into their thirties and occasionally into their forties [118]. This change in statistical trends increases the need for accurate and wide-scope information on outcomes for current DMD patients to better evaluate novel treatments. Eventually, death is caused most often by cardio-respiratory failure in patients that survive into their thirties and beyond, but some unexpected deaths do still occur in young patients [119]. The increasing lifespan of DMD patients has also changed the classification of this disease. Now with patients surviving well into adulthood, DMD is also considered an adulthood disease [75].

## **6.1 NOVEL TREATMENT STRATEGIES**

Many new treatments are currently being investigated for novel, more efficacious approaches to treating DMD. Novel treatment strategies include exon skipping, nonsense codon read-through, myostatin inhibitors, gene therapy through compensating protein upregulation, dystrophin transgene, microdystrophin, stem cell therapy, and clustered regularly interspaces short palindromic repeat (CRISPR) [120]. Each of these research categories provides both unique advantages and disadvantages that complicate an innovative breakthrough.

Exon skipping involves inducing the skipping of specific exons to restore the reading frame of the dystrophin protein to increase dystrophin expression in DMD patients [120,121]. This can, in theory, lead to a truncated but functional version of dystrophin. An approach being investigated is the use of antisense oligonucleotides to produce exon skipping (Figure 3)

[122]. One such novel drug, eteplirsen, is an uncharged phosphorodiamidate morpholino oligomer (PMO) used to skip exon 51 in DMD patients [123]. Eteplirsen is suitable to treat DMD patients with deletions ending at exon 50 and starting at exon 52, which accounts for ~20.5% of DMD deletion mutations and ~14% of DMD patients overall [43]. Eteplirsen has been shown to increase dystrophin-positive muscle fibers in DMD patients and improve ambulation and pulmonary function [120,124–126].




**Figure 3. Exon Skipping.** (A) Wild type dystrophin gene splicing with all normal functional exons. (B) Gene splicing in DMD with an exon 50 deletion of dystrophin. This results in mRNA with a premature termination codon (PTC) and non-functional dystrophin protein. Shown below is an exon therapy strategy resulting in mRNA without mutated exon 50 and PTC, yielding a shorter functional dystrophin.

Similar to eteplirsen, golodirsen is a PMO that is used to induce skipping of exon 53 in dystrophin [127]. Golodirsen is useful in about 7.7% of DMD patients and has been shown to increase dystrophin in DMD patients, however, the results regarding improved or prolonged ambulation are inconclusive [127–130][120]. Viltolarsen is another exon 53 skipping antisense oligonucleotide which has proven to increase dystrophin amount [120,131]. Casimersen is an antisense oligonucleotide for skipping of exon 45 of dystrophin and has shown to increase the amount of dystrophin in muscle. The expected phenotype after accomplishing accurate exon skipping is expected to resemble BMD and could prove a much better quality of life for DMD patients. Other exon-skipping compounds under investigation include SRP-5051, WVE-N531, DS-5141b, NS-089 (NCNP-020), and scAAV9.U7.ACCA [120]. Through the generation of specific exon skipping during mRNA splicing, antisense compounds were shown to rectify the *DMD* gene's reading frame and revitalize the dystrophin protein expression [132]. Further research is necessary to confirm the functional clinical benefit of exon skipping. Unfortunately, exon skipping might induce an innate immune response, reactivating dystrophin-specific T-cells and potentially limiting the technique's therapeutic capability [133].

Suppression of nonsense codons for DMD treatment is another major area of interest to the scientific community [120]. Premature stop codons are typically caused by single nucleotide substitution. Several compounds are under investigation for the intention of reading through or suppressing stop codons (Figure 4). Oligonucleotides are being used to repair specific

mutations, such as a single nucleotide substitution. Also, aminoglycoside antibiotics such as gentamicin are known to read through nonsense codons, potentially treating DMD caused by such mutations [134]. Ataluren is a drug that is thought to promote read-through of stop codons by insertion of near-cognate tRNAs at the stop codon site [135]. Clinical trials are ongoing for the effectiveness of ataluren in DMD, with some improvement seen with a six-minute walk test [136]. Regrettably, less than nine percent of DMD mutations are due to stop codons, causing this treatment strategy to only potentially cure a small fraction of DMD patients [43]. Also, stop codon readthrough and suppression might also cause a dystrophin-specific T-cell response, thus creating an immunogenicity obstacle in this possible treatment option [137].



**Figure 4. Stop Codon Read-Through.** Gene splicing in DMD with a missense mutation in exon 51 of dystrophin results in premature termination codon (PTC) and nonfunctional dystrophin. Stop codon read-through therapy resulting in full-length functional dystrophin expression.

Targeting growth factors is another prominent area of research in DMD, specifically myostatin. Myostatin is a **myokine** that inhibits muscle growth and differentiation through an autocrine pathway [138]. Since DMD is a progressively degenerative process that transforms muscle fibers into necrotic tissue, mechanisms that regenerate muscle tissue could be a potential therapeutic route. Myostatin inhibition causes significant muscle hypertrophy and hyperplasia [139]. Therefore, inhibiting myostatin could potentially lead to an increase in muscle growth in DMD patients. Mice models have suggested the efficacy of this approach and current clinical trials are underway to investigate the usefulness of myostatin inhibitors in DMD patients ([NCT03789734](#)) [120,140–142]. The use of follistatin **upregulation**, an endogenous myostatin inhibitor, is also being investigated ([NCT01761292](#), [NCT02354781](#), [NCT02851797](#), [NCT03373968](#)) [120,143]. In addition, selective androgen receptor modulators (SARMs) provide a new potential DMD treatment through androgen-driven muscle growth [144,145]. Unfortunately, though myostatin inhibitors **may** increase muscle growth in DMD patients, the regenerated muscle growth still lacks dystrophin and creates defective DMD muscle.

Gene therapy **is** a new and exciting field that could transform the way medicine is approached and cure many different diseases. Gene therapy can, unfortunately, cause an immune response in DMD patients because these patients lack naturally occurring functional dystrophin [120]. Inducing transgene dystrophin is recognized by the immune system as

foreign [146]. If dystrophin transgenes are used to treat DMD patients in the future, life-long immune suppression may be required.

Using gene therapy to create a functional dystrophin transgene has been an area of much interest in the treatment of DMD [120]. Previous research has explored utilizing adeno-associated viruses (AAV) to deliver a functional version of dystrophin to DMD patients [146]. However, the dystrophin gene has 79 exons, which is too large to fit into a recombinant adeno-associated virus (rAAV) [3]. To combat the size barrier of dystrophin, creating a functional but miniaturized dystrophin transgene has been sought as a solution and rAAV2.5-CMV-minidystrophin was engineered. This miniaturized dystrophin transgene has been shown to restore partial muscle strength in murine models with DMD and more research may prove this model to be a helpful treatment for DMD [120,147].

So far there has been no detection of dystrophin-specific antibodies in patients, making humoral immunity unlikely to affect genetic therapy in DMD. However, cellular immunity may prove to be a barrier to this treatment option. Dystrophin-specific T-cells have been detected upon treatment with a dystrophin transgene [3]. It must also be ensured that rAAV vectors can be delivered to all targeted muscle groups in DMD, especially the heart in which a lack of dystrophin causes cardiomyopathy. This need for widespread delivery yields its own surplus of obstacles in treatment [148,149]. Other smaller “micro-dystrophin” proteins are currently under investigation, such as SRP-9001 (NCT03769116), SGT-001 (NCT03368742), rAAVrh74.MCK.micro-dystrophin (NCT02376816), and PF-06939926 (NCT03362502) [120,150]. The use of AAV for surrogate gene therapy with GALGT2, a  $\beta$ 1,4 N-acetylgalactosaminyltransferase that glycosylates  $\alpha$ -dystroglycan, to help express dystrophin is also being investigated (NCT03333590) [151,152].

An alternative approach to DMD treatment is to attempt to strengthen DMD patients' muscles through modulation of other homologous or dystrophin-associated proteins. The upregulation of a substitutable protein for dystrophin could potentially compensate for the lack of dystrophin in DMD patients. One potential target includes the upregulation of utrophin, a protein only expressed during fetal development [153–155]. *Mdx* mouse models have been shown to alleviate some dystrophy symptoms through the production of utrophin [156]. Researchers hope to find a pharmacological agent that can produce utrophin in cells to treat DMD patients. Additionally, laminin-111, a protein necessary for fetal development, has shown promise in *mdx* mice models [157]. It has also been found that an enzyme hematopoietic prostaglandin D<sub>2</sub> synthase (HPGDS) may play a role in the necrosis of muscle tissue in DMD and is a target of inhibition (NCT02246478, NCT02752048, NCT04587908) [120,158,159]. Through inhibition of HPGDS, it is hypothesized that DMD progression could be slowed. Another therapeutic target is sarcospan (SSPN), a transmembrane protein that interacts with dystrophin and upregulates the utrophin-glycoprotein complex [160,161]. Furthermore, inhibition of sodium/proton type 1 exchanger (NHE-1) is being investigated for its role in sodium/calcium homeostasis in DMD muscle cells [162]. Rimeporide inhibits NHE-1 and is under investigation [120,163].

An additional therapeutic target for DMD is to reduce muscle fibrosis. Muscle fibrosis has been correlated with decreased muscle function in DMD patients [164]. Currently, a connective tissue growth factor (CTGF) inhibitor FG-3019 (pamrevlumab) suggested a benefit in mouse models and is undergoing clinical trials (NCT02606136, NCT04371666, NCT04632940) [120]. Tamoxifen, a selective estrogen receptor modulator may also reduce muscle fibrosis in DMD (NCT03354039) [120]. Moreover, anti-inflammatory drugs such as vamorolone (a novel steroid), CAT-1004 (an Nf-Kb inhibitor), flavocoxid (Nf-Kb inhibitor), and canakinumab (IL-1 antibody) are being investigated for efficacy in treating DMD [120,165–167]. This approach builds off the current mainstay treatment of glucocorticoids for DMD

treatment. An antisense oligonucleotide, ATL1102, is under investigation for its efficacy in reducing inflammation via inhibition of CD49d on T-cells (ACTRN12618000970246). In addition, CAP-1002 consists of cardiosphere-derived cells and is under investigation for its ability to reduce inflammation and treat DMD (NCT04428476) [168].

Another novel approach to treat DMD includes attempting to increase blood flow to muscles to help prevent fatigue. In DMD patients, neuronal nitric oxide synthase (nNOS) is deficient and may play a role in fatigue [169]. The use of phosphodiesterase inhibitors in DMD patients to restore muscle blood flow is underway and has shown benefit in *mdx* nNOS-deficient mice, but have thus far proven ineffective in clinical trials [120,170–172]. In addition, research is ongoing to investigate the use of nitric oxide, sodium nitrate (a nitric oxide donor), and nitric oxide precursors [120,173–175].

Several studies have proven the efficacy of using CRISPR-Cas9 to restore high levels of dystrophin in iPSCs and murine, canine, and porcine models [120,176–181]. Various strategies have been employed to utilize CRISPR to correct DMD mutations. These include double-cut myoediting, single-cut myoediting, and nucleotide myoediting, each with their own potential benefits and consequences [182]. Double-cut myoediting utilizes two sgRNAs to flank a mutated exon for removal. Single-cut myoediting utilizes one sgRNA around the intron-exon junction of an exon and introduces insertions or deletions to destroy the splicing consensus sequence and cause exon skipping. Nucleotide myoediting uses base editors to repair a single point-mutation [182]. CRISPR technology has also created novel animal models for DMD [183–186]. One issue, however, is the inability to create cardiac phenotypes in animal models identical to those seen in DMD patients [186]. Creating phenotypes in animal models that match the real DMD patient phenotypes is crucial for the implementation of this technology. The creation of mosaics has also been a troubling outcome of CRISPR use in this research [187]. Additionally, immunogenicity to the AVV used to encode CRISPR presents a barrier to treatment [188]. Another area of concern is that each animal model's innate systems express certain restrictions, such as unique anatomy, physiology, and size, that cannot represent all tissue type aspects in DMD patients [189]. A possible remedy for this issue is to use different animal models to represent the different physiological stages in the progression of DMD in patients. For example, using murine models to represent the initial phase of the disease, canine models to represent DMD patients from five to ten years of age, and rabbit models for the presentation of cardiac symptoms in DMD [189]. CRISPR/Casp9 gene editing has proved possible in patient-derived myoblasts, and more research is needed for this novel treatment approach, however there are concerns about off-target effects [120,190].

In addition to targeting skeletal muscle dysfunction and loss, research into treating and preventing cardiomyopathy in DMD patients is underway. Clinical trials examining the effects of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers (NCT03779646), and diuretics in the prevention and treatment of cardiomyopathy in DMD are ongoing [191–193]. Additional investigation is underway studying the effects of various other approaches. Antioxidants such as Coenzyme Q10 and Idebenone may be of use [120,194–197]. MA-0211 (ASP0367) a PPAR- $\delta$  selective modulator, Granulocyte-colony stimulating factor, stem cell therapy, and polyphenols are also under investigation [120].

## 6.2 ANALYSIS OF RETINAL DYSTROPHIN NOVEL THERAPY

The discovery of retinal dystrophin started with the observation that most boys with DMD have abnormal electroretinogram results [198–201]. These clinical findings led to the identification and cloning of the specific dystrophin isoform of 260 kDa. This Dp260 isoform

was given the common name “retinal dystrophin” due to the natural occurrence of this protein in the plexiform layer of the retina. However, it is important to note that 20-30% of DMD patients have normal electroretinograms, signifying that these patients have a genetic mutation in their dystrophin gene upstream of the Dp260 isoform and therefore express retinal dystrophin in their eyes [202].

Retinal dystrophin is an isoform of the full-length dystrophin protein and is related to muscle dystrophin. Retinal dystrophin has four functional domains and is classified as mini dystrophin [203]. Interestingly, retinal dystrophin contains the equivalent of all of the protein binding sites found in normal muscle dystrophin [203]. These Dp260 binding sites include an actin side-binding site located in the rod domain, the dystroglycan-sarcoglycan complex site in the cysteine-rich domain, and the syntrophin sites in the C-terminal domain [203]. Dp260 is primarily expressed in the retina but has been detected in other tissues through PCR, including the brain and cardiac tissue of mice. However, it is not expressed in the muscle tissue of mice [203].

To overcome the immunogenicity barrier presented in AAV therapy, White et. al have undertaken efforts to investigate the potential therapeutic value of utilizing the retinal dystrophin isoform Dp260 to restore dystrophin in DMD patients [204]. Activating the expression of retinal dystrophin in skeletal and cardiac muscle in DMD patients is an exciting prospect in which the body might be able to use an endogenous protein to treat DMD.

The breakthrough of the creation of a retinal dystrophin transgene was accomplished through genetic engineering, in which the promotor for Dp260 was replaced by a muscle promoter [204]. This retinal dystrophin transgene was observed to be relatively stable in MM14 muscle cells, suggesting that the Dp260 transgene was able to bind securely to other cellular proteins and may have possibly replaced the Dp427 muscle dystrophin in these cells [204]. Overall, retinal dystrophin expression assists in a stable association between a cell's cytoskeletal actin and sarcolemma construct and the dystrophin-glycoprotein complex and substantially slows the progression of muscle wasting in *mdx* mice [204].

Continuing research is being conducted on *mdx* and *mdx/utrn*<sup>-/-</sup> mice which express the retinal dystrophin transgene. The mice expressing the Dp260 transgene have been shown to display reduced amounts of inflammation and fibrosis in muscle tissue [204]. The *mdx/utrn*<sup>-/-</sup> Tg<sup>+</sup> mice do experience some muscle degeneration, though greatly reduced from untreated *mdx/utrn*<sup>-/-</sup> mice [204]. The *mdx/utrn*<sup>-/-</sup> Tg<sup>+</sup> mice experience attenuation of the skeletal and cardiac muscle phenotype common in DMD and survive the normal one-year life span, drastically increased from the *mdx/utrn*<sup>-/-</sup> lifespan of three months [204]. These results suggest that Dp260 presence in DMD diseased muscle tissue could prevent the severe consequences of this disease, resulting in a milder myopathy phenotype [205].

The retinal dystrophin transgene also seems to alleviate calcium channel dysfunction in DMD. Calcium dysregulation in DMD patients is hypothesized to cause cellular defects and possibly even cellular apoptosis in these already structurally unsound cells. Calcium channels have been observed to be defective due to the lack of dystrophin stabilization in affected patients' cells. However, the observation of dystrophin-associated protein beta-dystroglycan co-localizing with voltage-gated calcium channels in the retina implies that retinal dystrophin may be able to bind the beta-dystroglycan in muscle cells and counteract the calcium channel defect in DMD [204]. This observation could be monumental in overcoming the calcium channel defect inflicted in DMD patients.

The medical and research communities are surrounded by different potential philosophies that will lead to the next treatment or cure. One such philosophy highlights the importance of

how all the body's anatomy, physiology, immunology, etc. works together to perform high-functioning tasks. This thought highlights the potential retinal dystrophin treatment for DMD of using the body's naturally occurring resources and harnessing that creation to solve other complex issues experienced in the human body. The possibility of retinal dystrophin also possesses another clear advantage from other current research treatments for DMD. Retinal dystrophin is naturally occurring in nearly 30% of DMD patients that have an upstream mutation of the Dp260 region and will not be recognized as foreign by the immune system [204]. This innate protein in DMD patients is unlikely to cause an immune response. The probability of immunogenicity plagues other such potential DMD therapies and could cause even more obstacles for DMD patients to overcome after treatment.

Continuing research in retinal dystrophy for the treatment of DMD hopes to find a pharmaceutical able to induce Dp260 through a promoter in non-retinal cells. This retinal dystrophin expression in muscle cells might be able to attenuate the phenotype of DMD patients and allow these patients to experience a milder phenotype, as seen in other muscular dystrophies. By using naturally occurring structures in the body, treatments may be able to regenerate these complexes and unleash the brilliance of the complexity and sophistication of the human body's ability to cure itself.

## **7. CONCLUSION**

DMD is a muscular disease with catastrophic and fatal consequences. DMD arises due to de novo and inherited genetic mutations causing a lack of functional dystrophin, a critical protein necessary for muscle structure and function. DMD patients lose muscle function over time, ultimately losing ambulation by age 12. Patients often die by 30-40 years of age due to respiratory failure or cardiomyopathy. Diagnosis of DMD involves prenatal screening, genetic testing, muscle biopsies, and clinical features. Currently accepted treatments include corticosteroids, physical therapy, and respiratory assistance, none of which are curative. Various novel treatment strategies are under investigation including exon skipping, nonsense codon read-through, myostatin inhibitors, stem cell therapy, CRISPR, and retinal dystrophin. Given the devastating symptoms and early fatality of DMD, new treatment options are necessary to improve the lives of these patients and more research is needed to hopefully find a cure.

## **REFERENCES**

1. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loire JD, et al. Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's or Becker's Muscular Dystrophy. *N Engl J Med.* 1988;318(21):1363–8. DOI:10.1056/NEJM198805263182104. <http://www.nejm.org/doi/abs/10.1056/NEJM198805263182104>.
2. Emery AEH. The muscular dystrophies. *Lancet.* 2002;359(9307):687–95. DOI:10.1016/S0140-6736(02)07815-7. <http://www.thelancet.com/article/S0140673602078157/fulltext>.
3. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin Immunity in Duchenne's Muscular Dystrophy. *N Engl J Med.* 2010;363(15):1429–37. DOI:10.1056/NEJMoa1000228. <http://www.nejm.org/doi/abs/10.1056/NEJMoa1000228>.
4. Monaco AP, Kunkel LM. A giant locus for the Duchenne and Becker muscular dystrophy gene. *Trends Genet.* 1987;3:33–7. DOI:https://doi.org/10.1016/0168-9525(87)90163-6. <http://www.sciencedirect.com/science/article/pii/0168952587901636>.
5. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell.* 1988;53(2):219–28. DOI:10.1016/0092-8674(88)90383-2.
6. Uchino M, Araki S, Miike T, Teramoto H, Nakamura T, Yasutake T. Localization and

- characterization of dystrophin in muscle biopsy specimens from Duchenne muscular dystrophy and various neuromuscular disorders. *Muscle Nerve*. 1989;12(12):1009–16. DOI:10.1002/mus.880121209.
7. Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Determination of the exon structure of the distal portion of the dystrophin gene by vectorette PCR. *Genomics*. 1992;13(4):942–50. DOI:10.1016/0888-7543(92)90005-d.
  8. den Dunnen JT, Bakker E, Breteler EG, Pearson PL, van Ommen GJ. Direct detection of more than 50% of the Duchenne muscular dystrophy mutations by field inversion gels. *Nature*. 1987;329(6140):640–2. DOI:10.1038/329640a0.
  9. Lee T, Takeshima Y, Kusunoki N, Awano H, Yagi M, Matsuo M, et al. Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients. *J Hum Genet*. 2014;59(1):46–50. DOI:10.1038/jhg.2013.119.
  10. Becker PE, Kiener F. Eine neue x-chromosomale Muskeldystrophie. *Arch für Psychiatr und Nervenkrankheiten Ver mit Zeitschrift für die Gesamte Neurol und Psychiatr*. 1955;193(4):427–48. DOI:10.1007/BF00343141. <https://pubmed.ncbi.nlm.nih.gov/13249581/>.
  11. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. *Neuromuscul Disord*. 2014;24(6):482–91. DOI:10.1016/j.nmd.2014.03.008. <https://pubmed.ncbi.nlm.nih.gov/24780148/>.
  12. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. *Orphanet J Rare Dis*. 2020;15(1):141. DOI:10.1186/s13023-020-01430-8.
  13. Kariyawasam D, D’Silva A, Mowat D, Russell J, Sampaio H, Jones K, et al. Incidence of Duchenne muscular dystrophy in the modern era; an Australian study. *Eur J Hum Genet*. 2022;30(12):1398–404. DOI:10.1038/s41431-022-01138-2.
  14. Salzberg DC, Mann JR, McDermott S. Differences in Race and Ethnicity in Muscular Dystrophy Mortality Rates for Males under 40 Years of Age, 2006-2015. *Neuroepidemiology*. 2018;50(3–4):201–6. DOI:10.1159/000488244. <https://pubmed.ncbi.nlm.nih.gov/29698937/>.
  15. Kornberg A, Yiu E. Duchenne muscular dystrophy. *Neurol India*. 2008;56(3):236. DOI:10.4103/0028-3886.43441. <http://www.neurologyindia.com/text.asp?2008/56/3/236/43441>.
  16. Zubrzycka-Gaarn EE, Bulman DE, Karpati G, Burghes AHM, Belfall B, Klamut HJ, et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. *Nature*. 1988;333(6172):466–9. DOI:10.1038/333466a0. <https://pubmed.ncbi.nlm.nih.gov/3287171/>.
  17. Gao QQ, McNally EM. The Dystrophin Complex: Structure, Function, and Implications for Therapy. In: *Comprehensive Physiology*. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2015 [cited 2020 Nov 5]. p. 1223–39 DOI:10.1002/cphy.c140048. <http://doi.wiley.com/10.1002/cphy.c140048>.
  18. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin [homepage on the Internet]. Vol. 3, *Nature Genetics*. 1993 [cited 2020 Jul 24]. p. 283–91 DOI:10.1038/ng0493-283. <http://www.nature.com/articles/ng0493-283>.
  19. Henderson DM, Lin AY, Thomas DD, Ervasti JM. The carboxy-terminal third of dystrophin enhances actin binding activity. *J Mol Biol*. 2012;416(3):414–24. DOI:10.1016/j.jmb.2011.12.040. <https://linkinghub.elsevier.com/retrieve/pii/S0022283611013696>.
  20. Levine BA, Moir AJG, Patchell VB, Perry S V. The interaction of actin with dystrophin. *FEBS Lett*. 1990;263(1):159–62. DOI:10.1016/0014-5793(90)80728-2. <http://doi.wiley.com/10.1016/0014-5793%2890%2980728-2>.
  21. Way M, Pope B, Cross RA, Kendrick-Jones J, Weeds AG. Expression of the N-terminal domain of dystrophin in *E. coli* and demonstration of binding to F-actin. *FEBS Lett*. 1992;301(3):243–5. DOI:10.1016/0014-5793(92)80249-G.

- <http://doi.wiley.com/10.1016/0014-5793%2892%2980249-G>.
22. Amann KJ, Renley BA, Ervasti JM. A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. *J Biol Chem*. 1998;273(43):28419–23. DOI:10.1074/jbc.273.43.28419. <http://www.jbc.org/lookup/doi/10.1074/jbc.273.43.28419>.
  23. Suzuki A, Yoshida M, Ozawa E. Mammalian  $\alpha$ 1- and  $\beta$ 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. *J Cell Biol*. 1995;128(3):373–81. DOI:10.1083/jcb.128.3.373. <https://rupress.org/jcb/article-pdf/128/3/373/386689/373.pdf>.
  24. Ahn AH, Kunkel LM. Syntrophin binds to an alternatively spliced exon of dystrophin. *J Cell Biol*. 1995;128(3):363–71. DOI:10.1083/jcb.128.3.363. <http://rupress.org/jcb/article-pdf/128/3/363/386730/363.pdf>.
  25. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. *Cell*. 1991;66(6):1121–31. DOI:10.1016/0092-8674(91)90035-W. <http://www.cell.com/article/009286749190035W/fulltext>.
  26. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Vol. 12, *Current Opinion in Genetics and Development*. Elsevier Ltd; 2002. p. 349–61 DOI:10.1016/S0959-437X(02)00309-X.
  27. Yang B, Jung D, Rafael JA, Chamberlain JS, Campbell KP. Identification of  $\alpha$ -syntrophin binding to syntrophin triplet, dystrophin, and utrophin. *J Biol Chem*. 1995;270(10):4975–8. DOI:10.1074/jbc.270.10.4975. <http://www.jbc.org/content/270/10/4975.full>.
  28. Chang WJ, Iannaccone ST, Lau KS, Masters BSS, McCabe TJ, Mcmillan K, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. *Proc Natl Acad Sci U S A*. 1996;93(17):9142–7. DOI:10.1073/pnas.93.17.9142. <https://www.pnas.org/content/93/17/9142>.
  29. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. *Nature*. 2008;456(7221):511–5. DOI:10.1038/nature07414. <https://www.nature.com/articles/nature07414>.
  30. Doorenweerd N, Mahfouz A, Van Putten M, Kaliyaperumal R, T'Hoën PAC, Hendriksen JGM, et al. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. *Sci Rep*. 2017;7(1) DOI:10.1038/s41598-017-12981-5. <https://pubmed.ncbi.nlm.nih.gov/28974727/>.
  31. Matsuo M, Awano H, Matsumoto M, Nagai M, Kawaguchi T, Zhang Z, et al. Dystrophin Dp116: A yet to Be Investigated Product of the Duchenne Muscular Dystrophy Gene. *Genes (Basel)*. 2017;8(10) DOI:10.3390/genes8100251.
  32. Culligan KG, Mackey AJ, Finn DM, Maguire PB, Ohlendieck K. Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). *Int J Mol Med*. 1998;2(6):639–48. DOI:10.3892/ijmm.2.6.639.
  33. Aragón J, González-Reyes M, Romo-Yáñez J, Vacca O, Aguilar-González G, Rendón A, et al. Dystrophin Dp71 Isoforms Are Differentially Expressed in the Mouse Brain and Retina: Report of New Alternative Splicing and a Novel Nomenclature for Dp71 Isoforms. *Mol Neurobiol*. 2018;55(2):1376–86. DOI:10.1007/s12035-017-0405-x.
  34. Austin RC, Morris GE, Howard PL, Klamut HJ, Ray PN. Expression and synthesis of alternatively spliced variants of Dp71 in adult human brain. *Neuromuscul Disord*. 2000;10(3):187–93. DOI:10.1016/s0960-8966(99)00105-4.
  35. Tozawa T, Itoh K, Yaoi T, Tando S, Umekage M, Dai H, et al. The shortest isoform of dystrophin (Dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain. *Mol Neurobiol*. 2012;45(2):287–97. DOI:10.1007/s12035-012-8233-5.
  36. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. *Nature*. 1989;338(6212):259–62. DOI:10.1038/338259a0. <https://www.nature.com/articles/338259a0>.
  37. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the

- sarcolemma from stresses developed during muscle contraction. *Proc Natl Acad Sci U S A*. 1993;90(8):3710–4. DOI:10.1073/pnas.90.8.3710. <https://www.pnas.org/content/90/8/3710>.
38. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. *J Cell Biol*. 1995;128(3):355–61. DOI:10.1083/jcb.128.3.355. <http://rupress.org/jcb/article-pdf/128/3/355/386675/355.pdf>.
39. Johnstone VPA, Viola HM, Hool LC. Dystrophic cardiomyopathy—potential role of calcium in pathogenesis, treatment and novel therapies [homepage on the Internet]. Vol. 8, *Genes*. MDPI AG; 2017 [cited 2020 Nov 7]. DOI:10.3390/genes8040108. <https://pubmed.ncbi.nlm.nih.gov/28338606/>.
40. Bonilla E, Samitt CE, Miranda AF, Hays AP, Salviati G, DiMauro S, et al. Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface. *Cell*. 1988;54(4):447–52. DOI:10.1016/0092-8674(88)90065-7. <http://www.cell.com/article/0092867488900657/fulltext>.
41. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. *Am J Hum Genet*. 1991;49(1):54–67. </pmc/articles/PMC1683222/?report=abstract>.
42. Liechti-Gallati S, Koenig M, Kunkel LM, Frey D, Boltshauser E, Schneider V, et al. Molecular deletion patterns in Duchenne and Becker type muscular dystrophy. *Hum Genet*. 1989;81(4):343–8. DOI:10.1007/BF00283688. <https://pubmed.ncbi.nlm.nih.gov/2784778/>.
43. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD global database: Analysis of more than 7,000 duchenne muscular dystrophy mutations. *Hum Mutat*. 2015;36(4):395–402. DOI:10.1002/humu.22758. <https://onlinelibrary.wiley.com/doi/full/10.1002/humu.22758>.
44. Baumbach LL, Chamberlain JS, Ward PA, Farwell NJ, Caskey CT. Molecular and clinical correlations of deletions leading to duchenne and becker muscular dystrophies. *Neurology*. 1989;39(4):465–74. DOI:10.1212/wnl.39.4.465. <https://pubmed-ncbi-nlm-nih-gov.proxy.kcumb.edu/2927671/>.
45. Ferlini A, Neri M. *Molecular Genetics of Dystrophinopathies*. In: eLS. Chichester, UK: John Wiley & Sons, Ltd; 2014 [cited 2020 Nov 7]. DOI:10.1002/9780470015902.a0025342. <http://doi.wiley.com/10.1002/9780470015902.a0025342>.
46. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics*. 1988;2(1):90–5. DOI:10.1016/0888-7543(88)90113-9. <https://pubmed-ncbi-nlm-nih-gov.proxy.kcumb.edu/3384440/>.
47. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al. The molecular basis for duchenne versus becker muscular dystrophy: Correlation of severity with type of deletion. *Am J Hum Genet*. 1989;45(4):498–506. DOI:10.1016/1. </pmc/articles/PMC1683519/?report=abstract>.
48. Tuffery-Giraud S, Bérout C, Leturcq F, Yaou R Ben, Hamroun D, Michel-Calemard L, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase. *Hum Mutat*. 2009;30(6):934–45. DOI:10.1002/humu.20976. <https://pubmed.ncbi.nlm.nih.gov/19367636/>.
49. Soltanzadeh P, Friez MJ, Dunn D, von Niederhausern A, Gurvich OL, Swoboda KJ, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. *Neuromuscul Disord*. 2010;20(8):499–504. DOI:10.1016/j.nmd.2010.05.010. <https://pubmed-ncbi-nlm-nih-gov.proxy.kcumb.edu/20630757/>.
50. Chelly J, Marlhens F, Le Marec B, Jeanpierre M, Lambert M, Hamard G, et al. De novo DNA microdeletion in a girl with Turner syndrome and Duchenne muscular dystrophy. *Hum Genet*. 1986;74(2):193–6. DOI:10.1007/BF00282093. <https://pubmed-ncbi-nlm-nih-gov.proxy.kcumb.edu/2876949/>.
51. Quan F, Janas J, Toth-Fejfel S, Johnson DB, Wolford JK, Popovich BW. Uniparental disomy of the entire X chromosome in a female with Duchenne muscular dystrophy. *Am J*

- Hum Genet. 1997;60(1):160–5.
52. Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: A cohort study. *Lancet*. 1999;353(9170):2116–9. DOI:10.1016/S0140-6736(98)10028-4. <https://pubmed.ncbi.nlm.nih.gov.proxy.kcumb.edu/10382696/>.
53. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. *Nature*. 1986;323(6089):646–50. DOI:10.1038/323646a0.
54. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management [homepage on the Internet]. Vol. 17, *The Lancet Neurology*. Lancet Publishing Group; 2018 [cited 2020 Jul 16]. p. 251–67 DOI:10.1016/S1474-4422(18)30024-3. </pmc/articles/PMC5869704/?report=abstract>.
55. Emery AEH, Muntoni F, Quinlivan RCM. *Duchenne muscular dystrophy*. Oxford University Press; 2015.
56. Darras BT, Jones HR, Ryan MM, De Vivo DC. *Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach: Second Edition*. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach: Second Edition. Elsevier Inc.; 2014. DOI:10.1016/C2013-0-00077-1.
57. Olshen R, Cooper L, Wyatt M, Leach J, Mubarak S, Schultz P. The Pathomechanics of Gait in Duchenne Muscular Dystrophy. *Dev Med Child Neurol*. 1981;23(1):3–22. DOI:10.1111/j.1469-8749.1981.tb08442.x. <http://doi.wiley.com/10.1111/j.1469-8749.1981.tb08442.x>.
58. Pradhan S, Mittal B. Infraspinatus muscle hypertrophy and wasting of axillary folds as the important signs in Duchenne muscular dystrophy. *Clin Neurol Neurosurg*. 1995;97(2):134–8. DOI:10.1016/0303-8467(95)00013-A.
59. Engel-Hoek L Van Den, Van Alfen N, De Swart BJM, De Groot IJM, Pillen S. Quantitative ultrasound of the tongue and submental muscles in children and young adults. *Muscle Nerve*. 2012;46(1):31–7. DOI:10.1002/mus.23277. <http://doi.wiley.com/10.1002/mus.23277>.
60. Suresh S, Wales P, Dakin C, Harris M-A, Cooper D (Gus) M. Sleep-related breathing disorder in Duchenne muscular dystrophy: Disease spectrum in the paediatric population. *J Paediatr Child Health*. 2005;41(9–10):500–3. DOI:10.1111/j.1440-1754.2005.00691.x. <http://doi.wiley.com/10.1111/j.1440-1754.2005.00691.x>.
61. Dorman C, Hurley AD, Avignon JD. LANGUAGE AND LEARNING DISORDERS OF OLDER BOYS WITH DUCHENNE MUSCULAR DYSTROPHY. *Dev Med Child Neurol*. 2008;30(3):316–27. DOI:10.1111/j.1469-8749.1988.tb14556.x. <http://doi.wiley.com/10.1111/j.1469-8749.1988.tb14556.x>.
62. Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A, et al. Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy. *J Child Neurol*. 2015;30(11):1472–82. DOI:10.1177/0883073815570154. <http://journals.sagepub.com/doi/10.1177/0883073815570154>.
63. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol*. 2003;2(12):731–40. DOI:10.1016/s1474-4422(03)00585-4.
64. Leibowitz D, Dubowitz V. Intellect and Behaviour in Duchenne Muscular Dystrophy. *Dev Med Child Neurol*. 2008;23(6):577–90. DOI:10.1111/j.1469-8749.1981.tb02039.x. <http://doi.wiley.com/10.1111/j.1469-8749.1981.tb02039.x>.
65. Wu JY, Kuban KCK, Allred E, Shapiro F, Darras BT. Association of Duchenne Muscular Dystrophy With Autism Spectrum Disorder. *J Child Neurol*. 2005;20(10):790–5. DOI:10.1177/08830738050200100201.

<http://journals.sagepub.com/doi/10.1177/08830738050200100201>.

66. Hendriksen JGM, Vles JSH. Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive Disorder. *J Child Neurol*. 2008;23(5):477–81. DOI:10.1177/0883073807309775.

<http://journals.sagepub.com/doi/10.1177/0883073807309775>.

67. Annexstad EJ, Lund-Petersen I, Rasmussen M. Duchenne muscular dystrophy. *Tidsskr Nor Laegeforen*. 2014;134(14):1361–4. DOI:10.4045/tidsskr.13.0836.

68. Smith AD, Koreska J, Moseley CF. Progression of scoliosis in Duchenne muscular dystrophy. *J Bone Joint Surg Am*. 1989;71(7):1066–74.

69. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. *J Pediatr Orthop*. 2000;20(1):71–4.

70. Okinaka S, Kumagai H, Ebashi S, Sugita H, Momoi H, Toyokura Y, et al. Serum Creatine Phosphokinase: Activity in Progressive Muscular Dystrophy and Neuromuscular Diseases. *Arch Neurol*. 1961;4(5):520–5. DOI:10.1001/archneur.1961.00450110050006.

<https://jamanetwork.com/journals/jamaneurology/fullarticle/563253>.

71. McMillan HJ, Gregas M, Darras BT, Kang PB. Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. *Pediatrics*. 2011;127(1):e132–6.

DOI:10.1542/peds.2010-0929. <https://pediatrics.aappublications.org/content/127/1/e132>.

72. Chenard AA, Becane HM, Tertrain F, de Kermadec JM, Weiss YA. Ventricular arrhythmia in Duchenne muscular dystrophy: Prevalence, significance and prognosis. *Neuromuscul Disord*. 1993;3(3):201–6. DOI:10.1016/0960-8966(93)90060-W.

73. Yanagisawa A, Miyagawa M, Yotsukura M, Tsuya T, Shirato C, Ishihara T, et al. The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. *Am Heart J*. 1992;124(5):1244–50. DOI:10.1016/0002-8703(92)90407-M.

74. Nigro G, Comi LI, Politano L, Bain RJI. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int J Cardiol*. 1990;26(3):271–7. DOI:10.1016/0167-5273(90)90082-G.

75. Passamano L, Taglia A, Palladino A, Viggiano E, D'Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne Muscular Dystrophy: Retrospective analysis of 835 patients [homepage on the Internet]. Vol. 31, *Acta Myologica*. Pacini Editore; 2012 [cited 2020 Jul 17]. p. 121–5. [/pmc/articles/PMC3476854/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/11751186/).

76. Beck J, Weinberg J, Hamnegård CH, Spahija J, Olofson J, Grimby G, et al. Diaphragmatic function in advanced Duchenne muscular dystrophy. *Neuromuscul Disord*. 2006;16(3):161–7. DOI:10.1016/j.nmd.2006.01.003.

77. Phillips MF, Quinlivan RCM, Edwards RHT, Calverley PMA. Changes in spirometry over time as a prognostic marker in patients with duchenne muscular dystrophy. *Am J Respir Crit Care Med*. 2002;164(12):2191–4. DOI:10.1164/ajrccm.164.12.2103052. <https://pubmed.ncbi.nlm.nih.gov/11751186/>.

78. Van Den Engel-Hoek L, Erasmus CE, Hendriks JCM, Geurts ACH, Klein WM, Pillen S, et al. Oral muscles are progressively affected in Duchenne muscular dystrophy: Implications for dysphagia treatment. *J Neurol*. 2013;260(5):1295–303. DOI:10.1007/s00415-012-6793-y. <https://link.springer.com/article/10.1007/s00415-012-6793-y>.

79. Ioannou P, Christopoulos G, Panayides K, Kleanthous M, Middleton L. Detection of Duchenne and Becker muscular dystrophy carriers by quantitative multiplex polymerase chain reaction analysis. *Neurology*. 1992;42(9):1783–90. DOI:10.1212/wnl.42.9.1783. <https://n.neurology.org/content/42/9/1783>.

80. Okubo M, Minami N, Goto K, Goto Y, Noguchi S, Mitsuhashi S, et al. Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: Validation analysis of DMD mutations. *J Hum Genet*. 2016;61(6):483–9. DOI:10.1038/jhg.2016.7. [www.nature.com/jhg](http://www.nature.com/jhg).

81. Nevin J, Nevin NC, Dornan JC, Sim D, Armstrong MJ. Early amniocentesis: Experience of 222 consecutive patients, 1987–1988. *Prenat Diagn*. 1990;10(2):79–83.

- DOI:10.1002/pd.1970100203. <http://doi.wiley.com/10.1002/pd.1970100203>.
82. Ta MH, Tran TH, Do NH, Pham LAT, Bui TH, Ta VT, et al. Rapid method for targeted prenatal diagnosis of Duchenne muscular dystrophy in Vietnam. *Taiwan J Obstet Gynecol*. 2013;52(4):534–9. DOI:10.1016/j.tjog.2013.10.014.
83. Parks M, Court S, Cleary S, Clokie S, Hewitt J, Williams D, et al. Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage. *Prenat Diagn*. 2016;36(4):312–20. DOI:10.1002/pd.4781.
84. Lee SH, Kwak IP, Cha KEY, Park SE, Kim NK, Cha KEY, et al. Preimplantation diagnosis of non-deletion Duchenne muscular dystrophy (DMD) by linkage polymerase chain reaction analysis. *J Med Genet*. 1998;4(11):903–9. DOI:10.1136/jmg.30.11.903.
85. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. *Ann Neurol*. 2012;71(3):304–13. DOI:10.1002/ana.23528.
86. Tuffery-Giraud S, Saquet C, Chambert S, Echenne B, Marie Cuisset J, Rivier F, et al. The role of muscle biopsy in analysis of the dystrophin gene in Duchenne muscular dystrophy: experience of a national referral centre. *Neuromuscul Disord*. 2004;14(10):650–8. DOI:10.1016/j.nmd.2004.05.002.
87. Muntoni F. Is a muscle biopsy in Duchenne dystrophy really necessary? [homepage on the Internet]. Vol. 57, *Neurology*. Lippincott Williams and Wilkins; 2001 [cited 2020 Nov 7]. p. 574–5 DOI:10.1212/WNL.57.4.574. <https://n.neurology.org/content/57/4/574>.
88. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management [homepage on the Internet]. Vol. 9, *The Lancet Neurology*. Elsevier; 2010 [cited 2020 Nov 5]. p. 77–93 DOI:10.1016/S1474-4422(09)70271-6. <http://www>.
89. Voit T, Stuetzgen P, Cremer M, Goebel H. Dystrophin as a Diagnostic Marker in Duchenne and Becker Muscular Dystrophy. Correlation of Immunofluorescence and Western Blot. *Neuropediatrics*. 1991;22(03):152–62. DOI:10.1055/s-2008-1071434. <http://www.thieme-connect.de/DOI/DOI?10.1055/s-2008-1071434>.
90. Clarke A, Johnson M, Harris JB. Improved diagnosis of becker muscular dystrophy by dystrophin testing. *Neurology*. 1989;39(8):1011–7. DOI:10.1212/wnl.39.8.1011. <https://n.neurology.org/content/39/8/1011>.
91. Finanger EL, Russman B, Forbes SC, Rooney WD, Walter GA, Vandenborne K. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. *Phys Med Rehabil Clin N Am*. 2012;23(1):1–10, ix. DOI:10.1016/j.pmr.2011.11.004.
92. Shklyar I, Geisbush TR, Mijalovic AS, Pasternak A, Darras BT, Wu JS, et al. Quantitative muscle ultrasound in Duchenne muscular dystrophy: a comparison of techniques. *Muscle Nerve*. 2015;51(2):207–13. DOI:10.1002/mus.24296.
93. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. *J Hum Genet*. 2010;55(6):379–88. DOI:10.1038/jhg.2010.49. <https://pubmed.ncbi.nlm.nih.gov.proxy.kcumb.edu/20485447/>.
94. Falzarano M, Scotton C, Passarelli C, Ferlini A. Duchenne Muscular Dystrophy: From Diagnosis to Therapy. *Molecules*. 2015;20(10):18168–84. DOI:10.3390/molecules201018168. <http://www.mdpi.com/1420-3049/20/10/18168>.
95. den Dunnen JT, Beggs AH. Multiplex PCR for identifying DMD gene deletions. *Curr Protoc Hum Genet*. 2006;Chapter 9:Unit 9.3. DOI:10.1002/0471142905.hg0903s49.
96. Hegde MR, Chin ELH, Mulle JG, Okou DT, Warren ST, Zwick ME. Microarray-based mutation detection in the *dystrophin* gene. *Hum Mutat*. 2008;29(9):1091–9. DOI:10.1002/humu.20831. <http://doi.wiley.com/10.1002/humu.20831>.
97. Gatta V, Scarciolla O, Gaspari AR, Palka C, De Angelis MV, Di Muzio A, et al. Identification of deletions and duplications of the DMD gene in affected males and carrier

- females by multiple ligation probe amplification (MLPA). *Hum Genet.* 2005;117(1):92–8. DOI:10.1007/s00439-005-1270-7. <https://pubmed.ncbi.nlm.nih.gov/proxy.kcumb.edu/15841391/>.
98. Bovolenta M, Neri M, Fini S, Fabris M, Trabanelli C, Venturoli A, et al. A novel custom high density-comparative genomic hybridization array detects common rearrangements as well as deep intronic mutations in dystrophinopathies. *BMC Genomics.* 2008;9(1):572. DOI:10.1186/1471-2164-9-572. <http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-9-572>.
99. Wang Y, Yang Y, Liu J, Chen XC, Liu X, Wang CZ, et al. Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. *Mol Genet Genomics.* 2014;289(5):1013–21. DOI:10.1007/s00438-014-0847-z. <https://link.springer.com/article/10.1007/s00438-014-0847-z>.
100. Wang D, Gao M, Zhang K, Jin R, Lv Y, Liu Y, et al. Molecular Genetics Analysis of 70 Chinese Families With Muscular Dystrophy Using Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing. *Front Pharmacol.* 2019;10:814. DOI:10.3389/fphar.2019.00814. <https://www.frontiersin.org/article/10.3389/fphar.2019.00814/full>.
101. Xiao Y, Jiang X, Wang R. Screening for DMD/BMD Deletion Carriers by Fluorescence In Situ Hybridization. *Genet Test.* 2003;7(3):195–201. DOI:10.1089/109065703322537205. <https://pubmed.ncbi.nlm.nih.gov/proxy.kcumb.edu/14641995/>.
102. Pastore L, Caporaso MG, Frisso G, Orsini A, Santoro L, Sacchetti L, et al. A quantitative polymerase chain reaction (PCR) assay completely discriminates between Duchenne and Becker muscular dystrophy deletion carriers and normal females. *Mol Cell Probes.* 1996;10(2):129–37. DOI:10.1006/mcpr.1996.0018.
103. Jang W, Kim Y, Han E, Park J, Chae H, Kwon A, et al. Chromosomal microarray analysis as a first-tier clinical diagnostic test in patients with developmental delay/intellectual disability, autism spectrum disorders, and multiple congenital anomalies: A prospective multicenter study in Korea. *Ann Lab Med.* 2019;39(3):299–310. DOI:10.3343/alm.2019.39.3.299. [www.annlabmed.org](http://www.annlabmed.org) [https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK\\_Color\\_square.svg](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_square.svg).
104. Bennett RR, den Dunnen J, O'Brien KF, Darras BT, Kunkel LM. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. *BMC Genet.* 2001;2(1):1–12. DOI:10.1186/1471-2156-2-17. <https://link.springer.com/articles/10.1186/1471-2156-2-17>.
105. Torella A, Trimarco A, Blanco FDV, Cuomo A, Aurino S, Piluso G, et al. One hundred twenty-one dystrophin point mutations detected from stored DNA samples by combinatorial denaturing high-performance liquid chromatography. *J Mol Diagnostics.* 2010;12(1):65–73. DOI:10.2353/jmoldx.2010.090074. <https://pubmed.ncbi.nlm.nih.gov/30567556/>.
106. Uttley L, Carlton J, Woods HB, Brazier J. A review of quality of life themes in Duchenne muscular dystrophy for patients and carers [homepage on the Internet]. Vol. 16, Health and Quality of Life Outcomes. BioMed Central Ltd.; 2018 [cited 2020 Nov 5]. DOI:10.1186/s12955-018-1062-0. <https://pubmed.ncbi.nlm.nih.gov/30567556/>.
107. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. *Cochrane database Syst Rev.* 2008;(1):CD003725. DOI:10.1002/14651858.CD003725.pub3.
108. Biggar WD, Skalsky A, McDonald CM. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. *J Neuromuscul Dis.* 2022;9:463–76. DOI:10.3233/JND-210776.
109. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. In: *American Journal of Respiratory and Critical Care Medicine.* American Thoracic Society; 2004 [cited 2020 Nov 5]. p. 456–65 DOI:10.1164/rccm.200307-885ST.

- <http://www.atsjournals.org/doi/abs/10.1164/rccm.200307-885ST>.
110. Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. *Thorax*. 1998;53(11):949–52. DOI:10.1136/thx.53.11.949.
111. Klitzner TS, Beekman RH, Galieto FM, Jones TK, Manning PB, Morrow WR, et al. Cardiovascular health supervision for individuals affected by duchenne or becker muscular dystrophy. *Pediatrics*. 2005;116(6):1569–73. DOI:10.1542/peds.2005-2448. [www.aappublications.org/news](http://www.aappublications.org/news).
112. Manzur AY, Hyde SA, Rodillo E, Heckmatt JZ, Bentley G, Dubowitz V. A randomized controlled trial of early surgery in Duchenne muscular dystrophy. *Neuromuscul Disord*. 1992;2(5–6):379–87. DOI:10.1016/s0960-8966(06)80009-x.
113. Cheuk DKL, Wong V, Wraige E, Baxter P, Cole A. Surgery for scoliosis in Duchenne muscular dystrophy. *Cochrane database Syst Rev*. 2015;2015(10):CD005375. DOI:10.1002/14651858.CD005375.pub4.
114. Kennedy JD, Staples AJ, Brook PD, Parsons DW, Sutherland AD, Martin AJ, et al. Effect of spinal surgery on lung function in Duchenne muscular dystrophy. *Thorax*. 1995;50(11):1173–8. DOI:10.1136/thx.50.11.1173.
115. Hammer S, Toussaint M, Vollsæter M, Nesbjørg Tvedt M, Drange Røksund O, Reyhler G, et al. Exercise Training in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis. *J Rehabil Med*. 2022;54:jrm00250. DOI:10.2340/jrm.v53.985.
116. Bulut N, Karaduman A, Alemdaroğlu-Gürbüz İ, Yılmaz Ö, Topaloğlu H, Özçakar L. The effect of aerobic training on motor function and muscle architecture in children with Duchenne muscular dystrophy: A randomized controlled study. *Clin Rehabil*. 2022;36(8):1062–71. DOI:10.1177/02692155221095491. <https://doi.org/10.1177/02692155221095491>.
117. Lue YJ, Chen SS, Lu YM. Quality of life of patients with Duchenne muscular dystrophy: from adolescence to young men. *Disabil Rehabil*. 2017;39(14):1408–13. DOI:10.1080/09638288.2016.1196398. <https://www.tandfonline.com/doi/abs/10.1080/09638288.2016.1196398>.
118. Saito T, Kawai M, Kimura E, Ogata K, Takahashi T, Kobayashi M, et al. Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. *Neuromuscul Disord*. 2017;27(2):107–14. DOI:10.1016/j.nmd.2016.11.012.
119. Van Ruiten HJA, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Straub V, et al. Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. *Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc*. 2016;20(6):904–9. DOI:10.1016/j.ejpn.2016.07.020.
120. Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. *Lancet Neurol*. 2022;21(9):814–29. DOI:10.1016/S1474-4422(22)00125-9.
121. Van Deutekom JCT, Bremmer-Bout M, Janson AAM, Ginjaar IB, Baas F, Den Dunnen JT, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. *Hum Mol Genet*. 2001;10(15):1547–54. DOI:10.1093/hmg/10.15.1547. <https://academic.oup.com/hmg/article/10/15/1547/587689>.
122. Lim KRQ, Woo S, Melo D, Huang Y, Dzierlega K, Shah MNA, et al. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. *Proc Natl Acad Sci U S A*. 2022;119(9) DOI:10.1073/pnas.2112546119.
123. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Ann Neurol*. 2013;74(5):637–47. DOI:10.1002/ana.23982. <https://onlinelibrary.wiley.com/doi/full/10.1002/ana.23982>.
124. Alfano LN, Charleston JS, Connolly AM, Cripe L, Donoghue C, Dracker R, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy.

- Medicine (Baltimore). 2019;98(26):e15858. DOI:10.1097/MD.00000000000015858.  
/pmc/articles/PMC6617421/?report=abstract.
125. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Ann Neurol*. 2016;79(2):257–71. DOI:10.1002/ana.24555.  
<https://onlinelibrary.wiley.com/doi/full/10.1002/ana.24555>.
126. Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, et al. Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy. *Muscle Nerve*. 2022;66(3):262–9. DOI:10.1002/mus.27662.
127. Muntoni F, Frank D, Sardone V, Morgan J, Schnell F, Charleston J, et al. Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping (S22.001). *Neurology*. 2018;90(15 Supplement).
128. Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. *Neurology*. 2020;94(21):e2270–82. DOI:10.1212/WNL.0000000000009233.  
<https://n.neurology.org/content/94/21/e2270>.
129. Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, et al. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. *Nucleic Acid Ther*. 2022;32(1):29–39. DOI:10.1089/nat.2021.0043.
130. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, Van Deutekom J, Van Ommen GJ, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations [homepage on the Internet]. Vol. 30, *Human Mutation*. *Hum Mutat*; 2009 [cited 2020 Sep 22]. p. 293–9 DOI:10.1002/humu.20918.  
<https://pubmed.ncbi.nlm.nih.gov/19156838/>.
131. Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. *JAMA Neurol*. 2020;77(8):982–91. DOI:10.1001/jamaneurol.2020.1264. <https://jamanetwork.com/>.
132. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. *N Engl J Med*. 2007;357(26):2677–86. DOI:10.1056/NEJMoa073108.
133. Vila MC, Novak JS, Benny Klimek M, Li N, Morales M, Fritz AG, et al. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice. *J Pathol*. 2019;248(3):339–51. DOI:10.1002/path.5263.  
/pmc/articles/PMC6579705/?report=abstract.
134. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. *J Clin Invest*. 1999;104(4):375–81. DOI:10.1172/JCI7866.
135. Roy B, Friesen WJ, Tomizawa Y, Leszyk JD, Zhuo J, Johnson B, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. *Proc Natl Acad Sci U S A*. 2016;113(44):12508–13. DOI:10.1073/pnas.1605336113.  
[www.pnas.org/cgi/doi/10.1073/pnas.1605336113](http://www.pnas.org/cgi/doi/10.1073/pnas.1605336113).
136. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017;390(10101):1489–98. DOI:10.1016/S0140-6736(17)31611-2.
137. Goodenough E, Robinson TM, Zook MB, Flanigan KM, Atkins JF, Howard MT, et al. Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR. *Proc Natl Acad Sci U S A*. 2014;111(15):5670–5. DOI:10.1073/pnas.1402670111. [www.pnas.org/cgi/doi/10.1073/pnas.1402670111](http://www.pnas.org/cgi/doi/10.1073/pnas.1402670111).
138. Lee S-J. REGULATION OF MUSCLE MASS BY MYOSTATIN. *Annu Rev Cell Dev Biol*.

- 2004;20(1):61–86. DOI:10.1146/annurev.cellbio.20.012103.135836.  
<http://www.annualreviews.org/doi/10.1146/annurev.cellbio.20.012103.135836>.
139. Shieh PB. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy. *Neurother J Am Soc Exp Neurother*. 2018;15(4):840–8. DOI:10.1007/s13311-018-00687-z.
140. Bogdanovich S, Krag TOB, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. *Nature*. 2002;420(6914):418–21. DOI:10.1038/nature01154.  
<https://www.nature.com/articles/nature01154>.
141. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. *Ann Neurol*. 2002;52(6):832–6. DOI:10.1002/ana.10385.  
<https://onlinelibrary.wiley.com/doi/full/10.1002/ana.10385>.
142. Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. *Muscle Nerve*. 2017;55(4):458–64. DOI:10.1002/mus.25268. <http://doi.wiley.com/10.1002/mus.25268>.
143. Rodino-Klapac LR, Janssen PML, Shontz KM, Canan B, Montgomery CL, Griffin D, et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. *Hum Mol Genet*. 2013;22(24):4929–37. DOI:10.1093/hmg/ddt342.  
<https://academic.oup.com/hmg/article/22/24/4929/567402>.
144. Ponnusamy S, Sullivan R, Zafar N, Narayanan R. Tissue-Selective Androgen Receptor Modulators (SARMs) for the treatment of Duchenne muscular dystrophy (DMD). *Neuromuscul Disord*. 2016;26:S130. DOI:10.1016/j.nmd.2016.06.163. <http://www.nmd-journal.com/article/S0960896616304564/fulltext>.
145. Ponnusamy S, Sullivan RD, You D, Zafar N, Yang CH, Thiyagarajan T, et al. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy. *Hum Mol Genet*. 2017;26(13):2526–40. DOI:10.1093/hmg/ddx150.  
<https://academic.oup.com/hmg/article/26/13/2526/3770516>.
146. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J, et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product [homepage on the Internet]. Vol. 9, *Gene Therapy*. Nature Publishing Group; 2002 [cited 2020 Sep 24]. p. 1576–88 DOI:10.1038/sj.gt.3301829. [www.nature.com/gt](http://www.nature.com/gt).
147. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. *Nat Med*. 2006;12(7):787–9. DOI:10.1038/nm1439.
148. Muntoni F, Cau M, Ganau A, Congiu R, Arvedi G, Mateddu A, et al. Deletion of the Dystrophin Muscle-Promoter Region Associated with X-Linked Dilated Cardiomyopathy. *N Engl J Med*. 1993;329(13):921–5. DOI:10.1056/NEJM199309233291304.  
<http://www.nejm.org/doi/abs/10.1056/NEJM199309233291304>.
149. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. *Circulation*. 1993;87(6):1854–65. DOI:10.1161/01.CIR.87.6.1854. <https://www.ahajournals.org/doi/10.1161/01.CIR.87.6.1854>.
150. Schneider J, Gonzalez J, Brown K, Golebiowski D, Ricotti V, Quiroz J, et al. SGT-001 Micro-dystrophin gene therapy for Duchenne muscular dystrophy. *Neuromuscul Disord*. 2017;27:S188. DOI:10.1016/j.nmd.2017.06.343. <http://www.nmd-journal.com/article/S0960896617309161/fulltext>.
151. Chicoine LG, Rodino-Klapac LR, Shao G, Xu R, Bremer WG, Camboni M, et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin  $\alpha$ 2 surrogates. *Mol Ther*. 2014;22(4):713–24. DOI:10.1038/mt.2013.246.
152. Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, et al. A first-

in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. *Mol Ther - Methods Clin Dev.* 2022;27:47–60. DOI:<https://doi.org/10.1016/j.omtm.2022.08.009>. <https://www.sciencedirect.com/science/article/pii/S232905012200119X>.

153. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. *Cell.* 1997;90(4):717–27. DOI:10.1016/S0092-8674(00)80532-2.

154. Clerk A, Morris GE, Dubowitz V, Davies KE, Sewry CA. Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. *Histochem J.* 1993;25(8):554–61. DOI:10.1007/bf00173053. <https://link.springer.com/article/10.1007/BF00173053>.

155. Rigoletto C, Prella A, Ciscato P, Moggio M, Comi G, Fortunato F, et al. Utrophin expression during human fetal development. *Int J Dev Neurosci.* 1995;13(6):585–93. DOI:10.1016/0736-5748(95)00039-J. <http://doi.wiley.com/10.1016/0736-5748%2895%2900039-J>.

156. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. *Nature.* 1996;384(6607):349–53. DOI:10.1038/384349a0.

157. Rooney JE, Guppur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. *Proc Natl Acad Sci U S A.* 2009;106(19):7991–6. DOI:10.1073/pnas.0811599106. [www.pnas.org/cgi/doi/10.1073/pnas.0908890106](http://www.pnas.org/cgi/doi/10.1073/pnas.0908890106).

158. Tanaka K, Aritake K, Tayama M, Sasaki E, Utsugi T, Sasaoka T, et al. Novel inhibitor of hematopoietic prostaglandin D synthase improves the muscle disorder in an experimental model of Duchenne muscular dystrophy. *Neuromuscul Disord.* 2014;24(9–10):821. DOI:10.1016/j.nmd.2014.06.102. <http://www.nmd-journal.com/article/S0960896614002533/fulltext>.

159. Komaki H, Takeshita E, Motohashi Y, Ishiyama A, Sasaki M, Miyoshi K, et al. A Phase I, single- and repeated-dose study of TAS-205, a novel inhibitor of hematopoietic prostaglandin D synthase, in patients with Duchenne muscular dystrophy. *Neuromuscul Disord.* 2017;27:S218. DOI:10.1016/j.nmd.2017.06.445. <http://www.nmd-journal.com/article/S0960896617310180/fulltext>.

160. Peter AK, Marshall JL, Crosbie RH. Sarcospan reduces dystrophic pathology: Stabilization of the utrophin-glycoprotein complex. *J Cell Biol.* 2008;183(3):419–27. DOI:10.1083/jcb.200808027. [www.jcb.org/cgi/doi/10.1083/jcb.200808027](http://www.jcb.org/cgi/doi/10.1083/jcb.200808027).

161. Marshall JL, Oh J, Chou E, Lee JA, Holmberg J, Burkin DJ, et al. Sarcospan integration into laminin-binding adhesion complexes that ameliorate muscular dystrophy requires utrophin and  $\alpha 7$  integrin. *Hum Mol Genet.* 2014;24(7):2011–22. DOI:10.1093/hmg/ddu615. <https://academic.oup.com/hmg/article/24/7/2011/597194>.

162. Iwata Y, Katanosaka Y, Hisamitsu T, Wakabayashi S. Enhanced Na<sup>+</sup>/H<sup>+</sup> exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of p2 receptors. *Am J Pathol.* 2007;171(5):1576–87. DOI:10.2353/ajpath.2007.070452.

163. Previtali SC, Gidaro T, Díaz-Manera J, Zambon A, Carnesecchi S, Roux-Lombard P, et al. Rimeporide as a first-in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy. *Pharmacol Res.* 2020;159:104999. DOI:10.1016/j.phrs.2020.104999.

164. Desguerre I, Mayer M, Leturcq F, Barbet JP, Gherardi RK, Christov C. Endomysial fibrosis in duchenne muscular dystrophy: A marker of poor outcome associated with macrophage alternative activation. *J Neuropathol Exp Neurol.* 2009;68(7):762–73. DOI:10.1097/NEN.0b013e3181aa31c2. <https://pubmed-ncbi-nlm-nih-gov.proxy.kcumb.edu/19535995/>.

165. Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of

muscle function. *Neurology*. 2019;93(13):E1312–23. DOI:10.1212/WNL.0000000000008168. <https://n.neurology.org/content/93/13/e1312>.

166. Milne J, Donovan J, Sweeney L, Sleeper M, Hammers D, Jirousek M, et al. CAT-1004, a novel anti-inflammatory agent under development for treatment of Duchenne muscular dystrophy. *Neuromuscul Disord*. 2014;24(9–10):825. DOI:10.1016/j.nmd.2014.06.115. <http://www.nmd-journal.com/article/S0960896614002661/fulltext>.

167. Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, et al. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. *JAMA Netw Open*. 2022;5(1):e2144178–e2144178. DOI:10.1001/jamanetworkopen.2021.44178. <https://doi.org/10.1001/jamanetworkopen.2021.44178>.

168. Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. *Neurology*. 2019;92(8):e866 LP–e878. DOI:10.1212/WNL.0000000000006950. <http://n.neurology.org/content/92/8/e866.abstract>.

169. Wehling-Henricks M, Oltmann M, Rinaldi C, Myung KH, Tidball JG. Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. *Hum Mol Genet*. 2009;18(18):3439–51. DOI:10.1093/hmg/ddp288. <https://academic.oup.com/hmg/article/18/18/3439/554402>.

170. Adamo CM, Dai DF, Percival JM, Minami E, Willis MS, Patrucco E, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. *Proc Natl Acad Sci U S A*. 2010;107(44):19079–83. DOI:10.1073/pnas.1013077107. [www.pnas.org/cgi/doi/10.1073/pnas.1013077107](http://www.pnas.org/cgi/doi/10.1073/pnas.1013077107).

171. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. *J Pathol*. 2012;228(1):77–87. DOI:10.1002/path.4054. <http://doi.wiley.com/10.1002/path.4054>.

172. Nelson MD, Rader F, Tang X, Tavyev J, Nelson SF, Miceli MC, et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. *Neurology*. 2014;82(23):2085–91. DOI:10.1212/WNL.0000000000000498. <https://n.neurology.org/content/82/23/2085>.

173. Mizunoya W, Upadhya R, Burczynski FJ, Wang G, Anderson JE. Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm. *Am J Physiol Physiol*. 2011;300(5):C1065–77. DOI:10.1152/ajpcell.00482.2010. <https://www.physiology.org/doi/10.1152/ajpcell.00482.2010>.

174. Sciorati C, Miglietta D, Buono R, Pisa V, Cattaneo D, Azzoni E, et al. A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. *Pharmacol Res*. 2011;64(3):210–7. DOI:10.1016/j.phrs.2011.05.003.

175. Nelson MD, Rosenberry R, Barresi R, Tsimerinov EI, Rader F, Tang X, et al. Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy. *J Physiol*. 2015;593(23):5183–200. DOI:10.1113/JP271252. <http://doi.wiley.com/10.1113/JP271252>.

176. Li G, Jin M, Li Z, Xiao Q, Lin J, Yang D, et al. Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy. *J Clin Invest*. 2022; DOI:10.1172/JCI162809.

177. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. *Stem Cell Reports*. 2015;4(1):143–54. DOI:10.1016/j.stemcr.2014.10.013.

178. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that

cause duchenne muscular dystrophy. *Nat Commun.* 2015;6(1):1–13. DOI:10.1038/ncomms7244. [www.nature.com/naturecommunications](http://www.nature.com/naturecommunications).

179. Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, et al. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. *Nat Commun.* 2017;8(1):1–10. DOI:10.1038/ncomms14454. <http://www.dmd.nl>.

180. Min YL, Li H, Rodriguez-Caycedo C, Mireault AA, Huang J, Shelton JM, et al. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. *Sci Adv.* 2019;5(3):eaav4324. DOI:10.1126/sciadv.aav4324. <http://advances.sciencemag.org/>.

181. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. *Science* (80- ). 2014;345(6201):1184–8. DOI:10.1126/science.1254445. <https://science.sciencemag.org/content/345/6201/1184>.

182. Chemello F, Bassel-Duby R, Olson EN. Correction of muscular dystrophies by CRISPR gene editing. *J Clin Invest.* 2020;130(6):2766–76. DOI:10.1172/JCI136873.

183. Young CS, Mokhonova E, Quinonez M, Pyle AD, Spencer MJ. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy. *J Neuromuscul Dis.* 2017;4(2):139–45. DOI:10.3233/JND-170218.

184. Sui T, Lau YS, Liu D, Liu T, Xu L, Gao Y, et al. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9. *DMM Dis Model Mech.* 2018;11(6) DOI:10.1242/dmm.032201. <https://dmm.biologists.org/content/11/6/dmm032201>.

185. Shimo T, Hosoki K, Nakatsuji Y, Yokota T, Obika S. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping. *J Hum Genet.* 2018;63(3):365–75. DOI:10.1038/s10038-017-0400-0. <https://www.nature.com/articles/s10038-017-0400-0>.

186. Lim KRQ, Nguyen Q, Dzierlega K, Huang Y, Yokota T. CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy. *Genes (Basel).* 2020;11(3):342. DOI:10.3390/genes11030342. <https://www.mdpi.com/2073-4425/11/3/342>.

187. Mehravar M, Shirazi A, Nazari M, Banan M. Mosaicism in CRISPR/Cas9-mediated genome editing. Vol. 445, *Developmental Biology*. Elsevier Inc.; 2019. p. 156–62 DOI:10.1016/j.ydbio.2018.10.008.

188. Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. *Nat Med.* 2019;25(3):427–32. DOI:10.1038/s41591-019-0344-3. <https://www.nature.com/articles/s41591-019-0344-3>.

189. Wells DJ. Tracking progress: an update on animal models for Duchenne muscular dystrophy. Vol. 11, *Disease models & mechanisms*. 2018. DOI:10.1242/dmm.035774.

190. Wang D-N, Wang Z-Q, Jin M, Lin M-T, Wang N. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy. *Gene Ther.* 2022;29(12):730–7. DOI:10.1038/s41434-022-00336-3. <https://doi.org/10.1038/s41434-022-00336-3>.

191. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in duchenne muscular dystrophy. *Am J Cardiol.* 2012;110(1):98–102. DOI:10.1016/j.amjcard.2012.02.064.

192. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. *Am Heart J.* 2007;154(3):596–602. DOI:10.1016/j.ahj.2007.05.014.

193. Raman S V., Hor KN, Mazur W, Halnon NJ, Kissel JT, He X, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: A randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2015;14(2):153–61. DOI:10.1016/S1474-4422(14)70318-7.

194. Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJM, Schara U, et al. Idebeneone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial. *Neuromuscul Disord.* 2011;21(6):396–405. DOI:10.1016/j.nmd.2011.02.016.
195. Buyse GM, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): A double-blind randomised placebo-controlled phase 3 trial. *Lancet.* 2015;385(9979):1748–57. DOI:10.1016/S0140-6736(15)60025-3.
196. Meier T, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G, et al. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. *Neuromuscul Disord.* 2016;26(8):473–80. DOI:10.1016/j.nmd.2016.05.008.
197. Ren S, Yao C, Liu Y, Feng G, Dong X, Gao B, et al. Antioxidants for Treatment of Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis. *Eur Neurol.* 2022;85(5):377–88. DOI:10.1159/000525045. <https://www.karger.com/DOI/10.1159/000525045>.
198. Pillers DAM, Bulman DE, Weleber RG, Sigesmund DA, Musarella MA, Powell BR, et al. Dystrophin expression in the human retina is required for normal function as defined by electroretinography. *Nat Genet.* 1993;4(1):82–6. DOI:10.1038/ng0593-82. <https://www.nature.com/articles/ng0593-82>.
199. Fitzgerald KM, Cibis GW, Giambrone SA, Harris DJ. Retinal signal transmission in Duchenne muscular dystrophy: Evidence for dysfunction in the photoreceptor/depolarizing bipolar cell pathway. *J Clin Invest.* 1994;93(6):2425–30. DOI:10.1172/JCI117250.
200. Sigesmund DA, Weleber RG, Pillers DAM, Westall CA, Panton CM, Powell BR, et al. Characterization of the Ocular Phenotype of Duchenne and Becker Muscular Dystrophy. *Ophthalmology.* 1994;101(5):856–65. DOI:10.1016/S0161-6420(13)31249-4.
201. Barboni MTS, Joachimsthaler A, Roux MJ, Nagy ZZ, Ventura DF, Rendon A, et al. Retinal dystrophins and the retinopathy of Duchenne muscular dystrophy. *Prog Retin Eye Res.* 2022;101137. DOI:10.1016/j.preteyeres.2022.101137.
202. Pillers DA, Fitzgerald KM, Duncan NM, Rash SM, White RA, Dwinnell SJ, et al. Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations. *Hum Genet.* 1999;105(1–2):2–9. DOI:10.1007/s004399900111.
203. D'souza VN, Man NT, Morris GE, Karges W, Pillers DAM, Ray PN. A novel dystrophin isoform is required for normal retinal electrophysiology. *Hum Mol Genet.* 1995;4(5):837–42. DOI:10.1093/hmg/4.5.837. <https://academic.oup.com/hmg/article/4/5/837/708421>.
204. Gaedigk R, Law DJ, Fitzgerald-Gustafson KM, McNulty SG, Nsumu NN, Modrcin AC, et al. Improvement in survival and muscle function in an mdx/utrn(-/-) double mutant mouse using a human retinal dystrophin transgene. *Neuromuscul Disord.* 2006;16(3):192–203. DOI:10.1016/j.nmd.2005.12.007.
205. White RA, Silvey M, Logsdon DP. Research from the bedside to the lab bench & back. *Mo Med.* 2012;109(3):195–8.